<SEC-DOCUMENT>0001193125-24-076613.txt : 20240325
<SEC-HEADER>0001193125-24-076613.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325170405
ACCESSION NUMBER:		0001193125-24-076613
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240321
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		24780040

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d816036d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20240321" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-03-21_to_2024-03-21">SANGAMO THERAPEUTICS, INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-276">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-03-21_to_2024-03-21">0001001233</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="sgmo-20240321.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-03-21_to_2024-03-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-21</xbrli:startDate> <xbrli:endDate>2024-03-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-287">8-K</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt:datemonthdayyearen" id="ixv-288">March 21, 2024</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">SANGAMO THERAPEUTICS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:stateprovnameen" id="ixv-289">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-290">000-30171</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-291">68-0359556</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-292">501 Canal Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-293">Richmond</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:stateprovnameen" id="ixv-294">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-295">94804</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-296">(510)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-297">970-6000</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:boolballotbox" id="ixv-298">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:boolballotbox" id="ixv-300">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:boolballotbox" id="ixv-301">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-302">Common Stock, $0.01 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-303">SGMO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:exchnameen" id="ixv-304">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-03-21_to_2024-03-21" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2024, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> consistent with the rules of the Nasdaq Stock Market (the &#8220;Registered Direct Offering&#8221;), 24,761,905 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;) and <span style="white-space:nowrap">pre-funded</span> warrants to purchase up to an aggregate of 3,809,523 shares of Common Stock (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;), together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of Common Stock (the &#8220;Purchase Warrants,&#8221; and together with the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the &#8220;Warrants&#8221;). The combined offering price of each share of Common Stock and accompanying Purchase Warrant is $0.84. The combined offering price of each <span style="white-space:nowrap">Pre-Funded</span> Warrant and accompanying Purchase Warrant is $0.83 (equal to the combined purchase price per share of Common Stock and accompanying Purchase Warrant, minus $0.01). All of the securities being sold in this offering are being sold by Sangamo. The gross proceeds to Sangamo from the Registered Direct Offering are expected to be approximately $24.0&#160;million, before deducting the placement agents&#8217; fees and other offering expenses payable by the Company. The offering is expected to close on or about March&#160;26, 2024, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant will have an initial exercise price per share of $0.01, subject to certain adjustments. The <span style="white-space:nowrap">Pre-Funded</span> Warrants will be exercisable immediately and may be exercised at any time until all of the <span style="white-space:nowrap">Pre-Funded</span> Warrants are exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a <span style="white-space:nowrap">Pre-Funded</span> Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99%, 9.99% or 14.99% (at the election of the holder prior to the issuance of the <span style="white-space:nowrap">Pre-Funded</span> Warrant) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to the Company subject to the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Purchase Warrant will have an initial exercise price per share of $1.00, subject to certain adjustments. The Purchase Warrants will be exercisable six months after the date of issuance and may be exercised thereafter at any time until expiration five and a half years after the date of issuance. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Purchase Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% or 14.99% (at the election of the holder prior to the issuance of the Purchase Warrant) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to the Company subject to the terms of the Purchase Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties and agreements by Sangamo, customary conditions to closing, indemnification obligations of Sangamo, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc. and Cantor Fitzgerald&#160;&amp; Co. acted as the placement agents (the &#8220;Placement Agents&#8221;) in connection with the Registered Direct Offering pursuant to the Placement Agent Agreement, dated March&#160;21, 2024 (the &#8220;Placement Agent Agreement&#8221;), by and among the Company and the Placement Agents. Pursuant to the Placement Agent Agreement, the Placement Agents will be entitled to a cash fee equal to 6% of the gross proceeds raised in the Registered Direct Offering and reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">certain&#160;out-of-pocket&#160;expenses.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to Sangamo&#8217;s effective registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-255792)</span> previously filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and a prospectus supplement thereunder. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is only a brief description of the terms of the Warrants, Purchase Agreement and Placement Agent Agreement and does not purport to be a complete statement of the rights and obligations of the parties under the Warrants, Purchase Agreement, Placement Agent Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, form of Purchase Warrant, Purchase Agreement and Placement Agent Agreement that are filed as Exhibit 4.1, Exhibit 4.2, Exhibit 10.1 and Exhibit 10.2 hereto, respectively, and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the securities in the offering is attached as Exhibit 5.1 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains forward-looking statements, including, without limitation, statements relating to Sangamo&#8217;s expectations regarding the completion of the offering. These forward-looking statements are based upon Sangamo&#8217;s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the offering, the uncertain research and product development process, and other risks detailed in Sangamo&#8217;s filings with the SEC, including Sangamo&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023 and in the prospectus supplement relating to the offering, filed with the SEC on March&#160;25, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Sangamo undertakes no duty to update such information except as required under applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant to Purchase Common Stock. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex42.htm">Form of Warrant to Purchase Common Stock. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex51.htm">Opinion of Cooley LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex101.htm">Form of Securities Purchase Agreement, dated March&#160;21, 2024 by and among Sangamo Therapeutics, Inc. and the purchasers party thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex102.htm">Placement Agent Agreement, dated March&#160;21, 2024 by and among Sangamo Therapeutics, Inc. and Barclays Capital Inc. and Cantor Fitzgerald&#160;&amp; Co. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d816036dex51.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">SANGAMO THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ SCOTT B. WILLOUGHBY</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Scott B. Willoughby</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President, General Counsel and Corporate Secretary</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&#160;25, 2024 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d816036dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant
Shares: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Issuance: March 26, 2024 (such date, the &#147;<B><I>Issue Date</I></B>&#148;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No.: <FONT STYLE="white-space:nowrap">PF-[&#8195;</FONT> ] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> COMMON STOCK PURCHASE WARRANT</B> (the &#147;<B><I>Warrant</I></B>&#148;) certifies
that, for value received, the registered holder hereof or its permitted assigns (the &#147;<B><I>Holder</I></B>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or
after the Issue Date, to subscribe for and purchase from Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), up to &#8195;&#8195;&#8195;&#8195;shares (the &#147;<B><I>Warrant Shares</I></B>&#148;) of the
Company&#146;s common stock, par value $0.01 per share (&#147;<B><I>Common Stock</I></B>&#148;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant
is one of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Common Stock Purchase Warrants issued in connection with the transactions contemplated by that certain Securities Purchase Agreement, dated as of March 21, 2024, by and between the
Company and the Holder (the &#147;<B><I>Purchase Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <U>Definitions</U>. For
purposes of this Warrant, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Affiliate</I></B>&#148;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as
amended (the &#147;<B><I>1933 Act</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively,
the following Persons and entities: (i)&nbsp;any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issue Date, directly or indirectly managed or advised by the Holder&#146;s
investment manager or any of its Affiliates or principals, (ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any
of the foregoing and (iv)&nbsp;any other Persons whose beneficial ownership of Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Securities
Exchange Act of 1934, as amended (the &#147;<B><I>1934 Act</I></B>&#148;). For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage (as defined in Section&nbsp;2(e)).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg Financial Markets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Business Day</I></B>&#148; means any day except any Saturday, any Sunday, any day that is a federal legal
holiday in the United States or any day on which the New York Stock Exchange is authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the 1934 Act and as
defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Person</I></B>&#148; means an individual, a limited
liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Trading Day</I></B>&#148; means any day on which the Common Stock is traded on the Trading Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Trading Market</I></B>&#148; means the principal securities exchange or securities market, including an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, on which the Common Stock is then traded in the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Weighted Average Price</I></B>&#148; means, for any security as of any date, the dollar volume-weighted average
price for such security on the Trading Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its &#147;Volume at Price&#148; function or, if the
foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security
during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the
average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices). If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section&nbsp;5(n) with the term &#147;Weighted Average
Price&#148; being substituted for the term &#147;Exercise Price.&#148; All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exercise of Warrant</U>. Subject to the terms and conditions hereof, the purchase rights represented by this Warrant may
be exercised, in whole or in part, at any time or times on or after the Issue Date by delivery (whether via facsimile or otherwise) to the Company (or such other office or agency of the Company as it may designate by notice in writing to the
registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise form annexed hereto (the &#147;<B><I>Notice of Exercise</I></B>&#148;) and by payment to the Company of an amount
equal to the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer (or by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined below)). No
<FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. The Holder shall not be required to
physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case the Holder shall surrender this Warrant to the Company for
cancellation within three Trading Days after the date the Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares
purchased and the date of such purchases. <B>The </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
<B>Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.01, subject to
adjustment as provided herein (the &#147;<B><I>Exercise Price</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Delivery of Warrant Shares Upon Exercise</U>. Certificates for shares purchased hereunder shall be transmitted to the
Holder by crediting the account of the Holder&#146;s prime broker with The Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) through its Deposit/Withdrawal at Custodian (&#147;<B><I>DWAC</I></B>&#148;) system if the Company is then a
participant in such system and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is two Trading Days after the receipt by the Company of the Notice of Exercise (provided that payment of
the Exercise Price (or notification of Cashless Exercise, if applicable) has then been received by the Company) (such date, the &#147;<B><I>Warrant Share Delivery Date</I></B>&#148;). This Warrant shall be deemed to have been exercised upon proper
delivery of the Notice of Exercise and payment of the Exercise Price (or notification of Cashless Exercise). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed
to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised. The Company shall use commercially reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as
this Warrant remains outstanding and exercisable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Delivery of New Warrant Upon Exercise</U>. If this Warrant shall
have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(c)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date (other than a failure caused by incorrect or incomplete information provided by the Holder to the Company), and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then the Company shall either (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at
issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, or (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such
exercise was not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its
exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of this Warrant
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. In connection with the foregoing, the Holder shall
(i)&nbsp;use its reasonable efforts to notify the Company in advance of any pending exercise of this Warrant in order to enable to the Company to deliver the Warrant Shares by the Warrant Share Delivery Date and (ii)&nbsp;provide the Company written
notice within three Business Days after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the
Company, evidence of the amount of such loss. Subject to Section&nbsp;5(i), nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round (up or down) to the nearest whole share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Charges,
Taxes and Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <I>provided</I>, <I>however</I>, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment
of a sum sufficient to reimburse it for any transfer tax incidental thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Closing of Books</U>. The Company
will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Cashless Exercise</U>. Notwithstanding anything contained herein to the contrary, if at the time of exercise hereof a
registration statement registering the issuance of the Warrant Shares under the 1933 Act is not effective or available for the issuance of all of the Warrant Shares to the Holder (a &#147;<B><I>Registration Default</I></B>&#148;), then the Holder
may only exercise this Warrant, whether in whole or in part, and in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise Price, by effecting a cashless exercise of this
Warrant pursuant to which the Holder shall receive upon such cashless exercise the &#147;Net Number&#148; of Warrant Shares determined according to the following formula (a &#147;<B><I>Cashless Exercise</I></B>&#148;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Net Number</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=&nbsp;<U></U><U>(A&nbsp;x&nbsp;B) - (A&nbsp;x C)</U><U> </U><U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">A=&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">the total number of shares of Common Stock with respect to which this Warrant is then being exercised.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">B=&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">the Weighted Average Price of the shares of Common Stock on the date immediately preceding the date of the Notice of Exercise.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">C=&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, this Warrant may only be exercised by the Holder pursuant to a
Cashless Exercise if, and only if, at the time of exercise hereof, a Registration Default is then existing, as determined by the Company in good faith. If Warrant Shares are issued in such a Cashless Exercise, the Company acknowledges and agrees
that in accordance with Section&nbsp;3(a)(9) of the 1933 Act, the Warrant Shares shall take on the registered characteristics of the Warrant being exercised, and the holding period of the Warrant being exercised may be tacked on to the holding
period of the Warrant Shares. The Company agrees not to take any position contrary to this Section&nbsp;2(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U>Holder&#146;s Exercise Limitations</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this
Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that immediately prior to or after giving effect to such exercise, the Holder together with the
other Attribution Parties collectively would beneficially own in excess of [14.99][9.99][4.99]% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution
Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(A)&nbsp;exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of
the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or
exercise analogous to the limitation contained in this Section&nbsp;2(e). For purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the 1934 Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of
this Warrant is exercisable shall be in the sole discretion of the Holder, and the Company shall have no obligation to verify or confirm </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the 1934 Act and the
rules and regulations promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder
may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the Securities and Exchange Commission, as the case may be, (y)&nbsp;a more recent public announcement
by the Company or (z)&nbsp;any other written notice by the Company setting forth the number of shares of Common Stock outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Notice of Exercise from
the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding
and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;2(e), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of
Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the &#147;<B><I>Reduction Shares</I></B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the
Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written request of the Holder, the Company shall within five Business Days confirm orally and in writing or by electronic mail to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other
Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the 1934 Act), the number of shares so issued by
which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B><I>Excess Shares</I></B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the
Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the
Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage (not in excess of 19.99% of the issued and outstanding shares of
Common Stock immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of this Warrant if exceeding that limit would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) as
specified in such notice; <I>provided</I> that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the 61st day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to
the Holder and the other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the
Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the 1934 Act. No prior inability to exercise
this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with the intended beneficial ownership limitation contained in this Section&nbsp;2(e) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Subdivision or Combination </U><U>of Common Stock</U>. During such time as this Warrant is outstanding, if the Company
subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be
proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any
adjustment under this Section&nbsp;3(a) shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a) above, if during such time
as this Warrant is outstanding the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of shares of Common Stock (the &#147;<B><I>Purchase
Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, Section&nbsp;2(e) hereof) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<I>provided</I>, <I>however</I>, to the extent that
the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would
not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Pro Rata
Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &#147;<B><I>Distribution</I></B>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, Section&nbsp;2(e) hereof)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<I>provided</I>, <I>however</I>, to the extent that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or
indirectly, in one or more related transactions effects any merger or consolidation with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions (which, for the avoidance of doubt, shall not include a license or other agreement granting rights to intellectual property), (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of more than 50% of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or
any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a
stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other
Person acquires more than 50% of the outstanding shares of Common Stock (each a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (together, the &#147;<B><I>Alternate Consideration</I></B>&#148;), if any, receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock
are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Any such payment of such amount of such Alternative Consideration shall be made in the same form of consideration (whether securities, cash or property) as is given to the holders of Common Stock in such Fundamental
Transaction, and if multiple forms of consideration are given, the consideration shall be paid to the Holder in the same proportion as such consideration is paid to the holders of Common Stock. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section&nbsp;3(d) and insuring that this Warrant (or any such replacement security) will be similarly
adjusted upon any subsequent Fundamental Transaction. The Company shall cause any successor entity in a Fundamental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Transaction in which the Company is not the survivor (the &#147;<B><I>Successor Entity</I></B>&#148;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section&nbsp;3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of
such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of
capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, and without limiting Section&nbsp;2(e) hereof, the Holder may elect, at its sole option, by delivery of written notice to
the Company to waive this Section&nbsp;3(d) to permit a Fundamental Transaction without the assumption of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest whole
share, as the case may be. For purposes of this Section&nbsp;3, any calculation of the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall not include treasury shares, if any. Notwithstanding anything to the
contrary in this Section&nbsp;3, no adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% in such price; <I>provided</I> <I>however</I>, that any adjustments which by reason of
the immediately preceding sentence are not required to be made shall be carried forward and taken into account in any subsequent adjustment. In any case in which this Section&nbsp;3 shall require that an adjustment in the Exercise Price be made
effective as of a record date for a specified event, if Holder exercises this Warrant after such record date, the Company may elect to defer, until the occurrence of such event, the issuance of the shares of Common Stock and other capital stock of
the Company in excess of the shares of Common Stock and other capital stock of the Company, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; <I>provided</I>, <I>however</I>, that in such case
the Company shall deliver to the Holder a due bill or other appropriate instrument evidencing the Holder&#146;s right to receive such additional shares and/or other capital securities upon the occurrence of the event requiring such adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Par Value</U>. Notwithstanding anything to the contrary in this Warrant, in no event shall the Exercise Price be reduced
below the par value of the Company&#146;s Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company (or other designated agent), together with a written assignment of this Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the
name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company (or other designated agent), together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date set forth on the first page of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Warrant Register</U>. The Company shall initially serve as warrant agent under this Warrant. The Company shall register
ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B><I>Warrant Register</I></B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee
to which this Warrant is assigned hereunder) from time to time. Upon 30 days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation
resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business
shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the
Holder&#146;s last address as shown on the Warrant Register. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all
other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new
Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day
for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Authorized Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from
its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant (without regard to any limitations on exercise contained herein).
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon
the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this
Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, in each case to avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all
such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all
such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Governing Law</U>. This Warrant shall be governed by, and construed in accordance with, the laws of the State of New
York without giving effect to the conflicts of law principles thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Nonwaiver and Expenses</U>. No course of
dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Notice Procedures</U>. Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the date of transmission, if such notice or communication is delivered via email or facsimile at or
prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via email or facsimile on a day that is not a Trading Day or later than 5:30 p.m.
(New York City time) on any Trading Day, (c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or by International Federal Express, (d)&nbsp;the third Trading Day following the
date of mailing if sent by first-class registered or certified mail domestic, or (e)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">501
Canal Blvd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Richmond, California 94804 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Scott Willoughby </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [*] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">3 Embarcadero
Center, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Francisco, California 94111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chadwick L. Mills, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [*] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Holder:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">To the address, email address or facsimile number set forth in the Warrant Register, or as otherwise provided by the Holder to the
Company in accordance with this Section&nbsp;5(g)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Adjustment to Exercise Price</U>. Whenever the Exercise
Price or number of Warrant Shares is adjusted pursuant to any provision of Section&nbsp;3, the Company shall promptly provide the Holder a notice setting forth the Exercise Price and number of Warrant Shares after such adjustment and setting forth a
brief statement of the facts requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Notice to Allow Exercise by the Holder</U>. After the
Issue Date if (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company (which, for the avoidance of
doubt, shall not include a license or other agreement granting rights to intellectual property), or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register, at least 10 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of
which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; <I>provided</I> that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required
to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the
Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the
Company, whether such liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Remedies</U>. The
Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. Notwithstanding
the foregoing or anything else herein to the contrary, if the Company is for any reason unable to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to
the Holder any cash or other consideration or otherwise &#147;net cash settle&#148; this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Confidentiality</U>. The Holder agrees to keep confidential any
proprietary information relating to the Company delivered by the Company hereunder; provided that nothing herein shall prevent the Holder from disclosing such information: (i)&nbsp;to any holder of Warrants or Warrant Shares, (ii)&nbsp;to any
Affiliate of any holder of Warrants or Warrant Shares or any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section&nbsp;5(m), (iii) upon order, subpoena, or other process of any court or
administrative agency or otherwise required by law, (iv)&nbsp;upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v)&nbsp;which has been publicly disclosed without breach of any obligation to the
Company, (vi)&nbsp;which has been obtained from any Person that is not a party hereto or an Affiliate of any such party without any breach of any obligation to the Company, (vii)&nbsp;in connection with the exercise of any remedy, or the resolution
of any dispute hereunder, (viii)&nbsp;to the legal counsel or certified public accountants for any holder of Warrants or Warrant Shares, or (ix)&nbsp;as otherwise expressly contemplated by this Warrant. Notwithstanding the foregoing, the Company
shall not provide material, <FONT STYLE="white-space:nowrap">non-public</FONT> information or confidential or proprietary information to the Holder without such Holder&#146;s written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Dispute Resolution</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic
calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two Business Days of receipt of the Notice of Exercise giving rise to such dispute, as the case may be, to the
Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic calculation being submitted to the
Holder, then the Company shall, within two Business Days submit via facsimile (i)&nbsp;the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (ii)&nbsp;the
disputed arithmetic calculation of the Warrant Shares to the Company&#146;s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or
calculations and notify the Company and the Holder of the results no later than 10 Business Days from the time it receives the disputed determinations or calculations. Such investment bank&#146;s or accountant&#146;s determination or calculation, as
the case may be, shall be binding upon all parties absent demonstrable error. The expenses of the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise
Price or the arithmetic calculation of the Warrant Shares by the Holder was incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[remainder of page intentionally left blank] </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SANGAMO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sangamo Therapeutics, Inc. Pre-Funded Warrant] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: Sangamo Therapeutics, Inc. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned holder of Warrant No. PF-<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U><U></U>hereby elects
to &#8195;&#8195;&#8195; purchase &#8195;&#8195;&#8195; Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment shall take the form of (check applicable box): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise: lawful money of the United States; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cashless Exercise: the cancellation of such number of Warrant Shares as is necessary, in accordance with the
formula set forth in Section&nbsp;2(d), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in Section&nbsp;2(d). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By its delivery of this Notice of Exercise, the undersigned represents and warrants to the Company that in
giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted
to be owned under Section&nbsp;2(e) of the Warrant to which this notice relates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[SIGNATURE OF HOLDER]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Investing Entity</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Authorized Signatory of Investing Entity</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Authorized Signatory</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title of Authorized Signatory</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT FORM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To assign the foregoing warrant, execute </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">this form and supply required information. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Do not use this form to exercise the warrant.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR VALUE RECEIVED</B>, [ &#8195;&#8195;] all of or [&#8195;&#8195; ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>whose address is</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Signature</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Address:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without
alteration or enlargement or any change whatsoever. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>d816036dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant
Shares: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Issuance: March 26, 2024 (such date, the &#147;<B><I>Issue Date</I></B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This<B> COMMON STOCK PURCHASE WARRANT</B> (the &#147;<B><I>Warrant</I></B>&#148;) certifies that, for value received, the registered holder
hereof or its permitted assigns (the &#147;<B><I>Holder</I></B>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date and until 5:00 p.m., New York
time, on the Expiration Date (but not thereafter), to subscribe for and purchase from Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), up to &#8195;&#8195;&#8195; shares (the &#147;<B><I>Warrant
Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.01 per share (&#147;<B><I>Common Stock</I></B>&#148;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section&nbsp;2(b). This Warrant is one of the Common Stock Purchase Warrants issued in connection with the transactions contemplated by that certain Securities Purchase Agreement, dated as of March&nbsp;21, 2024, by and between the Company and the
Holder (the &#147;<B><I>Purchase Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <U>Definitions</U>. For purposes of this
Warrant, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Affiliate</I></B>&#148; means any Person
that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the
&#147;<B><I>1933 Act</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following
Persons and entities: (i)&nbsp;any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issue Date, directly or indirectly managed or advised by the Holder&#146;s investment manager or
any of its Affiliates or principals, (ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and
(iv)&nbsp;any other Persons whose beneficial ownership of Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Securities Exchange Act of
1934, as amended (the &#147;<B><I>1934 Act</I></B>&#148;). For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage (as defined in Section&nbsp;2(e)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg Financial Markets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Business Day</I></B>&#148; means any day except any Saturday, any Sunday, any day that is a federal legal
holiday in the United States or any day on which the New York Stock Exchange is authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Change of Control</I></B>&#148; means any Fundamental Transaction other than (i)&nbsp;any reorganization,
recapitalization or reclassification of the Common Stock in which holders of the Company&#146;s voting power immediately prior to such reorganization, recapitalization or reclassification continue after such reorganization, recapitalization or
reclassification to hold&nbsp;publicly traded securities and, directly or indirectly, the voting power of the surviving entity or entities necessary to elect a majority of the members of the board of directors (or their equivalent if other than a
corporation) of such entity or entities, or (ii)&nbsp;pursuant to a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or
other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Eligible Market</I></B>&#148; means the Trading Market, The New York Stock Exchange, Inc., the NYSE Amex
LLC, The Nasdaq Stock Market, or the OTC Bulletin Board<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<B><I>Expiration Date</I></B>&#148; means September&nbsp;26, 2029. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Group</I></B>&#148; means a
&#147;group&#148; as that term is used in Section&nbsp;13(d) of the 1934 Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock
or Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B><I>Person</I></B>&#148; means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B><I>Trading Day</I></B>&#148; means any day on which the Common Stock is traded on the Trading Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B><I>Trading Market</I></B>&#148; means the principal securities exchange or securities market, including an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, on which the Common Stock is then traded in the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B><I>Weighted Average Price</I></B>&#148; means, for any security as of any date, the dollar volume-weighted average
price for such security on the Trading Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its &#147;Volume at Price&#148; function or, if the
foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security
during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the
average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices). If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section&nbsp;5(n) with the term &#147;Weighted Average
Price&#148; being substituted for the term &#147;Exercise Price.&#148; All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exercise of Warrant</U>. Subject to the terms and conditions hereof, the purchase rights represented by this Warrant may
be exercised, in whole or in part, at any time or times on or after September&nbsp;26, 2024 and on or before the Expiration Date by delivery (whether via facsimile or otherwise) to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise form annexed hereto (the &#147;<B><I>Notice of Exercise</I></B>&#148;) and
by payment to the Company of an amount equal to the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer (or, if the provisions of Section&nbsp;2(d) are applicable, by notifying the Company that this Warrant is being
exercised pursuant to a Cashless Exercise (as defined below)). So long as this Warrant is held in book-entry form and the DTC is the sole registered holder of this Warrant, no <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. The Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case the Holder shall surrender this Warrant to the Company for cancellation within three Trading Days after the date the Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof. </B>For the avoidance of doubt, if the Holder does not exercise this Warrant prior to the expiration date, this Warrant shall expire unexercised, and the Company shall have no obligation to
settle the Warrant in cash, shares of Common Stock or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share
of Common Stock under this Warrant shall be $1.00, subject to adjustment as provided herein (the &#147;<B><I>Exercise Price</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Delivery of Warrant Shares Upon Exercise</U>. Certificates for shares purchased hereunder shall be transmitted by the
Company to the Holder by crediting the account of the Holder&#146;s prime broker with The Depository Trust Company (&#147;DTC&#148;) through its Deposit/Withdrawal at Custodian (&#147;<B><I>DWAC</I></B><B><I>&#148;</I></B>) system if the Company is
then a participant in such system by the date that is two Trading Days after the receipt by the Company of the Notice of Exercise and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise as soon as
commercially practicable (in each case, provided that payment of the Exercise Price (or notification of Cashless Exercise, if applicable) has then been received by the Company) (such date, the &#147;<B><I>Warrant Share Delivery Date</I></B>&#148;).
This Warrant shall be deemed to have been exercised upon proper delivery of the Notice of Exercise and payment of the Exercise Price (or notification of Cashless Exercise, if the provisions of Section&nbsp;2(d) are applicable). The Warrant Shares
shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised. The Company
shall use commercially reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Delivery of New Warrant Upon Exercise</U>. If this Warrant shall
have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(c)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date (other than a failure caused by incorrect or incomplete information provided by the Holder to the Company), and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then the Company shall either (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at
issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, or (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such
exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations
hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of this Warrant with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. In connection with the foregoing, the Holder shall (i)&nbsp;use its reasonable efforts
to notify the Company in advance of any pending exercise of this Warrant in order to enable to the Company to deliver the Warrant Shares by the Warrant Share Delivery Date and (ii)&nbsp;provide the Company written notice within three Business Days
after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such
loss. Subject to Section&nbsp;5(i), nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company&#146;s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round (up or down) to the nearest whole share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Charges, Taxes and Expenses</U>. Issuance of certificates for Warrant
Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by the Holder; <I>provided</I>, <I>however</I>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder (along with a medallion signature guarantee if requested by the and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Closing of Books</U>. The Company will
not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Cashless Exercise</U>. Notwithstanding anything contained herein to the contrary, if at the time of exercise hereof a
registration statement registering the issuance of the Warrant Shares under the 1933 Act is not effective or available for the issuance of all of the Warrant Shares to the Holder (a &#147;<B><I>Registration Default</I></B>&#148;), then the Holder
may only exercise this Warrant, whether in whole or in part, and in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise Price, by effecting a cashless exercise of this
Warrant pursuant to which the Holder shall receive upon such cashless exercise the &#147;Net Number&#148; of Warrant Shares determined according to the following formula (a &#147;<B><I>Cashless Exercise</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Number = <U></U><U>(A x B) - (A x C)</U><U> </U><U></U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:27%; font-size:10pt; font-family:Times New Roman">B </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of the foregoing formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the total number of shares of Common Stock with respect to which this Warrant is then being exercised.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B =</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Weighted Average Price of the shares of Common Stock on the date immediately preceding the date of the Notice of Exercise.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C =</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, this Warrant may only be exercised by the Holder pursuant to a
Cashless Exercise if, and only if, at the time of exercise hereof, a Registration Default is then existing, as determined by the Company in good faith. If Warrant Shares are issued in such a Cashless Exercise, the Company acknowledges and agrees
that in accordance with Section&nbsp;3(a)(9) of the 1933 Act, the Warrant Shares shall take on the registered characteristics of the Warrant being exercised, and the holding period of the Warrant being exercised may be tacked on to the holding
period of the Warrant Shares. The Company agrees not to take any position contrary to this Section&nbsp;2(d). </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Holder&#146;s Exercise Limitations</U>. Notwithstanding anything to
the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any
such exercise shall be null and void and treated as if never made, to the extent that immediately prior to or after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess
of [4.99][14.99]% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of
Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A)&nbsp;exercise of the remaining, unexercised portion of this Warrant
beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or
convertible preferred stock or warrants, including the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section&nbsp;2(e).
For purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section&nbsp;13(d) of the 1934 Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of
the Holder, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the
1934 Act and the rules and regulations promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum
Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the Securities and Exchange Commission, as the case may be, (y)&nbsp;a more recent public announcement by the
Company or (z)&nbsp;any other written notice by the Company setting forth the number of shares of Common Stock outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Notice of Exercise from the
Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding and,
to the extent that such Exercise Notice would otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;2(e), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of
Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the &#147;<B><I>Reduction Shares</I></B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the
Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written request of the Holder, the Company shall within five Business Days confirm orally and in writing or by electronic mail to the Holder
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon
exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under
Section&nbsp;13(d) of the 1934 Act), the number of shares so issued by which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B><I>Excess Shares</I></B>&#148;) shall
be deemed null and void and shall be cancelled ab initio and any portion of this Warrant so exercised shall be reinstated, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the
issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time
increase or decrease the Maximum Percentage to any other percentage (not in excess of 19.99% of the issued and outstanding shares of Common Stock immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of
this Warrant if exceeding that limit would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) as specified in such notice; <I>provided</I> that (i)&nbsp;any such increase in the Maximum Percentage will not be
effective until the 61st day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Warrants that is not an Attribution
Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for
purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this
paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e) to the extent
necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;2(e) or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Subdivision or Combination of Common Stock</U>. During such time as this Warrant is outstanding, if the Company
subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be
proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any
adjustment under this Section&nbsp;3(a) shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments
pursuant to Section&nbsp;3(a) above, if during such time as this Warrant is outstanding the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any
class of shares of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, Section&nbsp;2(e) hereof) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (<I>provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be
entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder
until such time, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#147;<B><I>Distribution</I></B>&#148;), at any time after the issuance of this Warrant, then, in
each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this
Warrant (without regard to any limitations on exercise hereof, including without limitation, Section&nbsp;2(e) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I>provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the
Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the
Maximum Percentage). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the
Company, directly or indirectly, in one or more related transactions effects any merger or consolidation with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions (which, for the avoidance of doubt, shall not include a license or other agreement granting rights to intellectual property), (iii) any, direct
or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or
property and has been accepted by the holders of more than 50% of the outstanding shares of Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (each a
&#147;<B><I>Fundamental Transaction</I></B>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant) the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the
surviving corporation, and any additional consideration (together, the &#147;<B><I>Alternate Consideration</I></B>&#148;), if any, receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall
be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.. Notwithstanding anything to the contrary, in the
event of a Change of Control, the Company or any Successor Entity shall, at the Holder&#146;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Change of Control (or, if later, the date of the public
announcement of the applicable Change of Control), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation
of such Change of Control;<I>&nbsp;provided</I>,<I>&nbsp;however</I>, if the Change of Control is not within the Company&#146;s control, including not approved by the Company&#146;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity, as of the date of consummation of such Change of Control, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is
being offered and paid to the holders of Common Stock of the Company in connection with the Change of Control, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the
choice to receive from among alternative forms of consideration in connection with the Change of Control;<I>&nbsp;provided,</I><I></I><I>&nbsp;further</I>, that if holders of Common Stock of the Company are not offered or paid any consideration in
such Change of Control, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Change of Control) in such Change of Control. &#147;<B><I>Black Scholes
Value</I></B>&#148; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg, L.P. determined as of the day of consummation of the applicable Change of Control for pricing
purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Change of Control and the Expiration Date, (B)&nbsp;an
expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg, L.P. (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Change
of Control, (C)&nbsp;the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, if any, being
offered in such Change of Control and (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the applicable Change of Control and the Expiration Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Trading Days of the Holder&#146;s election (or, if
later, on the effective date of the Fundamental Transaction)The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity in which the Company is not the
survivor (the &#147;<B><I>Successor Entity</I></B>&#148;) to comply with the provisions of this Section&nbsp;3(d) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent Fundamental
Transaction. The Company shall cause any Successor Entity to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the
occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the
&#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had
been named as the Company herein. Notwithstanding the foregoing, and without limiting Section&nbsp;2(e) hereof, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;3(d) to permit a
Fundamental Transaction without the assumption of this Warrant. . </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this
Section&nbsp;3 shall be made to the nearest cent or the nearest whole share, as the case may be. For purposes of this Section&nbsp;3, any calculation of the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall not include treasury shares, if any. Notwithstanding anything to the contrary in this Section&nbsp;3, no adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% in such
price; <I>provided</I> <I>however</I>, that any adjustments which by reason of the immediately preceding sentence are not required to be made shall be carried forward and taken into account in any subsequent adjustment. In any case in which this
Section&nbsp;3 shall require that an adjustment in the Exercise Price be made effective as of a record date for a specified event, if Holder exercises this Warrant after such record date, the Company may elect to defer, until the occurrence of such
event, the issuance of the shares of Common Stock and other capital stock of the Company in excess of the shares of Common Stock and other capital stock of the Company, if any, issuable upon such exercise on the basis of the Exercise Price in effect
prior to such adjustment; <I>provided</I>, <I>however</I>, that in such case the Company shall deliver to the Holder a due bill or other appropriate instrument evidencing the Holder&#146;s right to receive such additional shares and/or other capital
securities upon the occurrence of the event requiring such adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Par Value</U>. Notwithstanding anything to the contrary in this
Warrant, in no event shall the Exercise Price be reduced below the par value of the Company&#146;s Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company (or other designated agent), together with a written assignment of this Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney (along with a medallion signature guarantee if requested by the Company) and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new
Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company (or other designated agent), together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined
in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date set forth on the first page of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Warrant Register</U>. The Company shall initially serve as warrant agent under this Warrant. The
Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B><I>Warrant Register</I></B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the
case may be, any assignee to which this Warrant is assigned hereunder) from time to time. Upon 30 days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be
merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or
shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <U>Miscellaneous.
</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as Stockholder Until Exercise</U>. Except as set forth in Section&nbsp;3(c), this Warrant does not
entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company
covenants that upon receipt by the Company evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of
indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Saturdays, Sundays, Holidays, etc</U>. If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Authorized Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from
its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant (without regard to any limitations on exercise contained herein).
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon
the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this
Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, in each case to avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all
such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all
such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Governing Law</U>. This Warrant shall be governed by, and construed in accordance with, the laws of the State of New
York without giving effect to the conflicts of law principles thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or
failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company
willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Notice Procedures</U>. Any and all notices or other communications or deliveries required or permitted to be provided
hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the date of transmission, if such notice or communication is delivered via email or facsimile at or prior to 5:30 p.m. (New York City time) on a
Trading Day, (b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via email or facsimile on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day,
(c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or by International Federal Express, (d)&nbsp;the third Trading Day following the date of mailing if sent by first-class
registered or certified mail domestic, or (e)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">501
Canal Blvd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Richmond, California 94804 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Scott Willoughby </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [*] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">3 Embarcadero
Center, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Francisco, California 94111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chadwick L. Mills, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [*] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Holder:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">To the address, email address or facsimile number set forth in the Warrant Register, or as otherwise provided by the Holder to the
Company in accordance with this Section&nbsp;5(g)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Adjustment to Exercise Price</U>. Whenever the Exercise
Price or number of Warrant Shares is adjusted pursuant to any provision of Section&nbsp;3, the Company shall promptly, but in no event later than two (2)&nbsp;Trading Days after such adjustment, provide the Holder a notice setting forth the Exercise
Price and number of Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Notice to Allow Exercise by the Holder</U>. After the Issue Date
and on or prior to the Expiration Date, if (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of
the Common Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any
stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company
(which, for the avoidance of doubt, shall not include a license or other agreement granting rights to intellectual property), or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or
(E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear
upon the Warrant Register, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; <I>provided</I> that the failure to mail such notice or any defect therein or in
the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and
hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. Notwithstanding the foregoing or anything else herein to the contrary, if the Company is for any reason unable to
issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to the Holder any cash or other consideration or otherwise &#147;net cash settle&#148; this Warrant.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of any
Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Amendment</U>. This Warrant may be modified or amended or the
provisions hereof waived with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Confidentiality</U>. The Holder agrees to keep confidential any proprietary information relating to the Company
delivered by the Company hereunder; provided that nothing herein shall prevent the Holder from disclosing such information: (i)&nbsp;to any holder of Warrants or Warrant Shares, (ii)&nbsp;to any Affiliate of any holder of Warrants or Warrant Shares
or any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section&nbsp;5(m), (iii) upon order, subpoena, or other process of any court or administrative agency or otherwise required by law,
(iv)&nbsp;upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v)&nbsp;which has been publicly disclosed without breach of any obligation to the Company, (vi)&nbsp;which has been obtained from any
Person that is not a party hereto or an Affiliate of any such party without any breach of any obligation to the Company, (vii)&nbsp;in connection with the exercise of any remedy, or the resolution of any dispute hereunder, (viii)&nbsp;to the legal
counsel or certified public accountants for any holder of Warrants or Warrant Shares, or (ix)&nbsp;as otherwise expressly contemplated by this Warrant. Notwithstanding the foregoing, the Company shall not provide material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information or confidential or proprietary information to the Holder without such Holder&#146;s written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Dispute Resolution</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic
calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two Business Days of receipt of the Notice of Exercise giving rise to such dispute, as the case may be, to the
Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic calculation being submitted to the
Holder, then the Company shall, within two Business Days submit via facsimile (i)&nbsp;the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (ii)&nbsp;the
disputed arithmetic calculation of the Warrant Shares to the Company&#146;s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or
calculations and notify the Company and the Holder of the results no later than 10 Business Days from the time it receives the disputed determinations or calculations. Such investment bank&#146;s or accountant&#146;s determination or calculation, as
the case may be, shall be binding upon all parties absent demonstrable error. The expenses of the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise
Price or the arithmetic calculation of the Warrant Shares by the Holder was incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[remainder of page intentionally left blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SANGAMO THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Sangamo Therapeutics, Inc. Warrant]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: Sangamo Therapeutics, Inc. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned hereby elects to purchase &#8195;&#8195;&#8195;&#8195; Warrant Shares of the Company pursuant
to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment shall take the form of (check applicable box): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise: lawful money of the United States; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cashless Exercise (if permitted pursuant to Section&nbsp;2(d) of the Warrant): the cancellation of such number
of Warrant Shares as is necessary, in accordance with the formula set forth in Section&nbsp;2(d), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
Section&nbsp;2(d). For the avoidance of doubt, this Warrant may only be exercised by the Holder pursuant to a Cashless Exercise if, and only if, at the time of exercise hereof, a Registration Default is then existing, as determined by the Company in
good faith. See Section&nbsp;2(d) of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#8195;&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#8195;&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER]</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Investing Entity</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature of Authorized Signatory of Investing Entity</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT FORM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To assign the foregoing warrant, execute </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">this form and supply required information. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Do not use this form to exercise the warrant.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR VALUE RECEIVED</B>, [&#8195;&#8195; ] all of or [&#8195;&#8195; ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">whose address is</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without
alteration or enlargement or any change whatsoever. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d816036dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816036g77j47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Courtney Tygesson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1 312
881 6680 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ctygesson@cooley.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;25, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 Canal Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richmond, California 94804 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the offering of (i)
24,761,905 shares (the &#147;<B><I>Shares</I></B>&#148;) of its common stock, par value $0.01 per share (the &#147;<B><I>Common Stock</I></B>&#148;); (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B>&#148;) to purchase up to 3,809,523 shares of Common Stock (the &#147;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</I></B>&#148;); and (iii)&nbsp;accompanying
warrants (together with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the &#148;<B><I>Warrants</I></B>&#148;) to purchase up to 28,571,428 shares of Common Stock (together with the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares, the &#147;<B><I>Warrant Shares</I></B>&#148;), pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-255792)</FONT> (as amended by Post-Effective Amendment No.&nbsp;1 and Post-Effective Amendment No.&nbsp;2, the &#147;<B><I>Registration Statement</I></B>&#148;) filed with the Securities and Exchange
Commission (the &#147;<B><I>Commission</I></B>&#148;) by the Company under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), the prospectus included in the Registration Statement (the &#147;<B><I>Base
Prospectus</I></B>&#148;) and the prospectus supplement relating to the Shares, the Warrants and the Warrant Shares, dated March&nbsp;21, 2024, filed with the Commission pursuant to Rule 424(b) under the Securities Act (together with the Base
Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the
Prospectus, the forms of the Warrants, the Company&#146;s certificate of incorporation and bylaws, each as currently in effect, and such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as
copies; the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are
prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to our opinion as to the Warrant Shares, we express no opinion to the extent that future issuances of securities of the Company, antidilution
adjustments to outstanding securities of the Company or other matters cause the Warrants to be exercisable for more shares of Common Stock than the number that then available for issuance by the Company. Further, we have assumed the exercise price
of the Warrants will not be adjusted to an amount below the par value per share of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to our opinion concerning the Warrants
constituting valid and binding obligations of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;Our opinion is subject to, and may be limited by,
(a)&nbsp;applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance, debtor and creditor, and similar laws which relate to or affect creditors&#146; rights generally, and (b)&nbsp;general principles of equity (including,
without limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law. </P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><BR>Cooley LLP&#8194; 110 N. Wacker Drive, Suite 4200&#8194; Chicago,
IL&#8194; 60606-1511 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (312) 881-6500&#8194; f: (312) 881-6598&#8194; cooley.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816036g77j47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 25, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;Our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies
is subject to the discretion of the court before which the request is brought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;We express no opinion as to any provision of
the Warrants that: (a)&nbsp;provides for liquidated damages, <FONT STYLE="white-space:nowrap">buy-in</FONT> damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute
unlawful penalties, (b)&nbsp;relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c)&nbsp;restricts <FONT
STYLE="white-space:nowrap">non-written</FONT> modifications and waivers, (d)&nbsp;provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e)&nbsp;relates to exclusivity, election or
accumulation of rights or remedies, (f)&nbsp;authorizes or validates conclusive or discretionary determinations, or (g)&nbsp;provides that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined
to be invalid and unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;We express no opinion as to whether a state court outside of the State of New York or a
federal court of the United States would give effect to the choice of New York law or jurisdiction provided for in the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed
solely with respect to the General Corporation Law of the State of Delaware and, as to the Warrants constituting binding obligations of the Company, the laws of the State of New York. We express no opinion to the extent that any other laws are
applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, in reliance thereon and subject to the qualifications set forth herein, we are of the opinion that (i)&nbsp;the Shares, when
sold and issued against payment therefor in accordance with the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable, (ii)&nbsp;the Warrants, when duly executed by the Company and delivered to the
purchasers thereof against payment therefor as described in the Registration Statement and the Prospectus, will be binding obligations of the Company and (iii)&nbsp;the Warrant Shares, when issued and paid for in accordance with the terms of the
Warrants, will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters expressly set forth in this letter, and no opinion
should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we undertake no obligation or responsibility to update or supplement this letter
to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the
reference to our firm under the heading &#147;Legal Matters&#148; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Commission
for incorporation by reference into the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
of the Commission thereunder. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><BR>Cooley LLP&#8194; 110 N. Wacker
Drive, Suite 4200&#8194; Chicago, IL&#8194; 60606-1511 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (312) 881-6500&#8194; f: (312) 881-6598&#8194; cooley.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816036g77j47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 25, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Three </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>OOLEY</SMALL> LLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Courtney Tygesson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Courtney Tygesson</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><BR>Cooley LLP&#8194; 110 N. Wacker Drive,
Suite 4200&#8194; Chicago, IL&#8194; 60606-1511 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (312) 881-6500&#8194; f: (312) 881-6598&#8194; cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d816036dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Securities Purchase Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is dated as of March&nbsp;21, 2024, between Sangamo
Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, a &#147;<B><I>Purchaser</I></B>&#148; and
collectively the &#147;<B><I>Purchasers</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> subject to the terms and conditions set forth in this Agreement
and pursuant to an effective registration statement under the Securities Act of 1933, as amended (including the rules and regulations promulgated thereunder, the &#147;<B><I>Securities Act</I></B>&#148;), the Company desires to issue and sell to
each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, IN CONSIDERATION</B> of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree, severally and not jointly, as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms have the meanings set forth in this Section&nbsp;1.1: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquiring Person</I></B>&#148; has the meaning ascribed
to such term in Section&nbsp;4.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Action</I></B>&#148; means any action, suit, inquiry, notice of violation, arbitration,
complaint, proceeding (including any partial proceeding such as a deposition) or investigation pending or, to the knowledge of the Company, threatened in writing against the Company, any Subsidiary or any of their respective properties or any
officer, director or employee of the Company or any Subsidiary acting in his or her capacity as an officer, director or employee before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency,
regulatory authority, stock market, stock exchange or trading facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means any Person that,
directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; has the meaning ascribed to such term in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Applicable Laws</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(q). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Authorizations</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(q). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board of Directors</I></B>&#148; means the board of directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day other than Saturday, Sunday or other
day on which commercial banks in the City of New York, New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Bylaws</I></B>&#148; means the Company&#146;s Fifth Amended and Restated Bylaws, as in effect on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate of Incorporation</I></B>&#148; means the Company&#146;s Restated Certificate of Incorporation, as in effect on the
date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing</I></B>&#148; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Date</I></B>&#148; means the Trading Day on which all of the Transaction Documents have been executed and delivered
by the applicable parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&#146; obligations to pay the Subscription Amount and (ii)&nbsp;the Company&#146;s obligations to deliver the Securities, in each case, have been satisfied or
waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company, par value $0.01 per share, and any other class of securities
into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock Warrants</I></B>&#148; means the warrants
to purchase shares of Common Stock delivered to the Purchasers at Closing in accordance with Section&nbsp;2.2(a) hereof, in the form of Exhibit A attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock Equivalents</I></B>&#148; means any securities of the Company or the Subsidiaries which would entitle the holder
thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; has the meaning ascribed to such term in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Counsel</I></B>&#148; means Cooley LLP, with offices located at 3 Embarcadero Center, 20th Floor, San Francisco,
California 94111. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disclosure Time</I></B>&#148; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading
Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof and (ii)&nbsp;if this Agreement is signed between
midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>DGCL</I></B>&#148; means the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Environmental Laws</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(x). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FCPA</I></B>&#148; means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FDA</I></B>&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FINRA</I></B>&#148; means the Financial Industry Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Hazardous Materials</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(x). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual Property Rights</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(p). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>IT Systems</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(jj). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B>&#148; means each <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement, dated as of the date hereof, by and among the Company and each of the directors and officers of the Company, in the form of Exhibit B attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Material Adverse Effect</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Money Laundering Laws</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(ee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Personal Data</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(jj). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Per Share Purchase Price</I></B>&#148; means $0.84 (inclusive of the purchase price per Common Stock Warrant), which represents
the closing price of the Common Stock on the date hereof, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement;
<I>provided </I>that the purchase price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant (inclusive of the purchase price per Common Stock Warrant) shall be the Per Share Purchase Price minus $0.01. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Placement Agents</I></B>&#148; mean Barclays Capital Inc. and Cantor
Fitzgerald&nbsp;&amp; Co., whom the Company has engaged as its placement agents in connection with the placement of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B>&#148; means the warrants to purchase shares of Common Stock
delivered to the Purchasers at Closing in accordance with Section&nbsp;2.2(a) hereof, in the form of <U>Exhibit C</U> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Principal Trading Market</I></B>&#148; means the Trading Market on which the Common Stock is primarily listed on and quoted for
trading, which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Proceeding</I></B>&#148; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal
investigation or partial proceeding, such as a deposition), whether commenced or threatened in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prospectus</I></B>&#148; means the final base prospectus filed for the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prospectus Supplement</I></B>&#148; means the supplement to the Prospectus complying with Rule 424(b) that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Purchaser</I></B>&#148; has the meaning ascribed to
such term in the preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registration Statement</I></B>&#148; means the effective Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-255792)</FONT> which registers the sale of the Securities to the Purchasers, including all documents incorporated or deemed to be incorporated by reference
therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Required Minimum</I></B>&#148; means, as of any date, the maximum aggregate number of shares of Common Stock
potentially issuable in the future pursuant to the Transaction Documents, including any Warrant Shares issuable upon exercise in full of all Warrants ignoring any exercise limits set forth therein and the effect of potential future adjustments to
the exercise price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 144</I></B>&#148; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC Reports</I></B>&#148; has the meaning ascribed to such term in Section&nbsp;3.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities</I></B>&#148; means the Shares and the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; has the meaning ascribed to such term in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Shares</I></B>&#148; means the shares of Common Stock issued to each Purchaser pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Short Sales</I></B>&#148; means all &#147;short sales&#148; as defined in Rule
200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subscription Amount</I></B>&#148; means, as to each Purchaser, the aggregate amount to be paid for the Securities purchased
hereunder, in United States dollars and in immediately available funds, as set forth below such Purchaser&#146;s name on the signature page of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means any significant subsidiary of the Company within the meaning of Rule
<FONT STYLE="white-space:nowrap">1-02(w)</FONT> under Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading
Day</I></B>&#148; means a day on which the Principal Trading Market is open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transaction Documents</I></B>&#148; means this Agreement, the
Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer Agent</I></B>&#148; means Computershare, Inc., the current transfer agent of the Company, and any successor transfer
agent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Warrants</I></B>&#148; means the Common Stock Warrants and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Warrant Shares</I></B>&#148; means the shares of Common Stock
issuable upon exercise of the Warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AND SALE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and each Purchaser, severally and not jointly, agree to purchase, up to an aggregate of $24,000,000 of Securities. Each
Share or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be accompanied by a Common Stock Warrant to purchase one share of Common Stock. Each Purchaser&#146;s Subscription Amount as set forth on the signature page hereto executed by
such Purchaser shall be made available for &#147;Delivery Versus Payment (&#147;<B><I>DVP</I></B>&#148;) settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Securities pursuant to
Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur remotely
by electronic transfer of the Closing documentation or at such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company
shall issue the Shares registered in the Purchasers&#146; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall
promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Deliveries.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) legal opinion of Company Counsel, directed to the Placement Agent, in form and substance reasonably satisfactory to the
Placement Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company shall have provided each Purchaser with the Company&#146;s wire instructions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) subject to Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via the Depository Trust Company Deposit or Withdrawal at Custodian system (&#147;<B><I>DWAC</I></B>&#148;) Shares equal to the Purchaser&#146;s Subscription Amount divided by the Per Share Purchase Price, registered
in the name of such Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a Common Stock Warrant registered in the name of each Purchaser to purchase up to a
number of shares of Common Stock as set forth below such Purchaser&#146;s name on its signature page hereto, with an exercise price equal to $1.00 per share, subject to adjustment as set forth therein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) if applicable, a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant registered in the name of such Purchaser to
purchase up to a number of shares of Common Stock as set forth below such Purchaser&#146;s name on its signature page hereto, with an exercise price equal to $0.01 per share, subject to adjustment as set forth therein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rules 172 under the Securities Act);
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) on the date hereof, the duly executed <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by such Purchaser; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) such Purchaser&#146;s Subscription Amount, which shall be made available for DVP settlement with the Company or its
designee; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing Conditions.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or
Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless made as of a specific date therein in which case they shall be accurate in all material
respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall
have been performed; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b) of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the
following conditions being met: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be
accurate in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall
have been performed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Company of the items set forth in Section&nbsp;2.2(a) of this Agreement;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or
the Principal Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose
trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of
hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or
inadvisable to purchase the Securities at the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to the
Purchasers as of the date hereof and as of the Closing Date (except for the representations that speak as of a specific date, which shall be made as of such date) except as otherwise described in the SEC Reports, which qualify these representations
and warranties in their entirety: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>SEC Reports</U><I>.</I> The Company&#146;s reports, schedules, forms, statements
and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, during the twelve months preceding the date hereof (the foregoing materials, including
the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#147;<B><I>SEC Reports</I></B>&#148;), when they were filed with the Commission, conformed in all material respects to the
requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Financial Statements</U><I>.</I> The financial statements (including the related notes
thereto) of the Company and its consolidated subsidiaries included in the SEC Reports comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material
respects the financial position of the Company and its consolidated Subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been
prepared in conformity with generally accepted accounting principles in the United States (&#147;<B><I>GAAP</I></B>&#148;) applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included in the SEC Reports
present fairly in all material respects the information required to be stated therein; and the other financial information included in the SEC Reports has been derived from the accounting records of the Company and its consolidated Subsidiaries and
presents fairly the information shown thereby. No other financial statements or supporting schedules are required to be included in the SEC Reports. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Material Adverse Change</U><I>.</I> Since the date of the most recent financial statements of the Company included in
the SEC Reports, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in the SEC Reports, and the grant of 11,136,050
restricted stock units under existing equity incentive plans described in the SEC Reports), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment,
paid or made by the Company on any class of capital stock, or any material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of
operations or prospects of the Company and its Subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its Subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is
material to the Company and its Subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its Subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its
Subsidiaries has sustained any loss or interference with its business that is material to the Company and its Subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, including a health epidemic or pandemic
outbreak of infectious disease, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise
disclosed in the SEC Reports. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Organization and Good Standing</U><I>.</I> The Company and each of its Subsidiaries
have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective
ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,
except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial
position, stockholders&#146; equity, results of operations or prospects of the Company and its Subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;<B><I>Material Adverse
Effect</I></B>&#148;). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company&#146;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Capitalization</U><I>.</I> The Company has an
authorized capitalization as set forth in the SEC Reports; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and
are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in the SEC Reports or expressly contemplated by this Agreement, there are no outstanding rights (including, without limitation, <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its Subsidiaries, or any
contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options;
the capital stock of the Company conforms in all material respects to the description thereof contained in the SEC Reports; and all the outstanding shares of capital stock or other equity interests of each Subsidiary owned, directly or indirectly,
by the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> except as otherwise described in the SEC Reports, and are owned directly or indirectly by the Company, free
and clear of any material lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Due Authorization</U><I>.</I> The Company has full right, power and
authority to execute and deliver this Agreement and each of the other Transaction Documents to which it is a party and to perform its obligations hereunder and thereunder, including the issuance of the Securities in accordance with the terms hereof
and thereof; all action required to be taken for the due and proper authorization, execution and delivery by the Company of this Agreement and each of the other Transaction Documents to which it is a party, and the consummation by it of the
transactions contemplated hereby and thereby, including without limitation, the issuance of the Securities pursuant to this Agreement, has been duly and validly taken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Agreement</U><I>. </I>This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>The Securities</U><I>. </I>The Securities to be issued and sold by the Company hereunder have been duly authorized and,
when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Shares is not subject to any preemptive or similar
rights. The Warrants in the form attached hereto as <U>Exhibit A</U> have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this Agreement, will constitute valid and legally binding agreements of
the Company, enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by equitable principles relating
to enforceability. The Warrant Shares have been duly authorized and reserved for issuance pursuant to the terms of the Warrants, and when the Warrant Shares are issued by the Company upon valid exercise of the Warrants, such Warrant Shares will be
validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and not subject to any preemptive rights, rights of first refusal or similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Stock Exchange Listing</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and is
listed on the Principal Trading Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the
Principal Trading Market, nor has the Company received any notification that the Commission or the Principal Trading Market is contemplating terminating such registration or listing, except as disclosed in the SEC Reports. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>No Violation or Default</U><I>.</I> Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its
charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or
observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its
Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject; or (iii)&nbsp;in violation of any law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such
default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Conflicts</U><I>. </I>The execution, delivery and performance by the Company of the Transaction Documents, the
issuance and sale of the Securities and the consummation of the transactions contemplated thereby will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in
the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its Subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject, (ii)&nbsp;result in any violation of the
provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or any of its Subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>No Consents Required</U><I>.</I> No
consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of any of the
Transaction Documents, the issuance and sale of the Securities and the consummation of the transactions contemplated by the Transaction Documents, except for such registrations or qualifications as may be required under applicable state securities
laws in connection with the purchase and sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Legal Proceedings</U><I>.</I> Except as described
in the SEC Reports, there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its Subsidiaries is or may be a party or to which any property of the Company or any of its
Subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its Subsidiaries, would reasonably be expected to have a Material Adverse Effect; no such investigations, actions, suits
or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and there are no current or pending legal, governmental or regulatory actions, suits or proceedings
that are required under the Exchange Act to be described in the SEC Reports that are not so described therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)
<U>Independent Auditors</U>. Ernst&nbsp;&amp; Young LLP, who have audited certain financial statements of the Company and its Subsidiaries, is an independent registered public accounting firm with respect to the Company and its Subsidiaries within
the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Title to Real and Personal Property</U>. The Company and its
Subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective
businesses of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of
such property by the Company and its Subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Intellectual Property</U>. To the knowledge of the Company with respect to patents, patent applications, trade and
service marks, trade and service mark registrations, and trade names only, the Company and its Subsidiaries own, possess, or license, and otherwise have legally enforceable rights to all patents, patent applications, trade and service marks, trade
and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, and <FONT STYLE="white-space:nowrap">know-how,</FONT> except with regard to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software provided by third parties, (collectively, the &#147;<B><I>Intellectual Property Rights</I></B>&#148;) necessary for the conduct of the
Company&#146;s business as now conducted or, to the knowledge of the Company, as proposed in the SEC Reports to be conducted. Except as disclosed in the SEC Reports, (i)&nbsp;to the knowledge of the Company, there are no rights of third parties to
any such Intellectual Property Rights that conflict with the Company&#146;s right to own, possess or license, as applicable, such Intellectual Property Rights; (ii)&nbsp;the Company is not aware of any material infringement by third parties of any
such Intellectual Property Rights; (iii)&nbsp;there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others challenging the Company&#146;s rights in or to own, possess and license such Intellectual
Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (iv)&nbsp;there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others challenging
the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, except for any such action, suit, proceeding or claim that would not reasonably be
expected to have a Material Adverse Effect; (v)&nbsp;there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others that the Company infringes or otherwise violates any patent, trademark, copyright,
trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any such claim, except for any such action, suit, proceeding or claim that would not reasonably be expected to
have a Material Adverse Effect; (vi)&nbsp;to the knowledge of the Company, there is no U.S. patent or published U.S. patent application (other than U.S. patents or U.S. patent applications of the Company) which contains claims that dominate or may
dominate any Intellectual Property Rights described in the SEC Reports as being owned by or licensed to the Company or that interferes with the issued or pending claims of any such Intellectual Property Rights, except for such claims and
interferences that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; (vii)&nbsp;there is no prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or
any U.S. patent application held by the Company unpatentable which has not been disclosed to the U.S. Patent and Trademark Office, and (viii)&nbsp;to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
knowledge of the Company, all pertinent prior art references known to the Company or its counsel during the prosecution of<I> </I>the patents and patent applications comprising the Intellectual
Property Rights were disclosed to the relevant patent authority and, to the knowledge of the Company, neither such counsel nor the Company nor any licensor made any misrepresentation to, or concealed any material fact from, the relevant patent
authority during such prosecution and the Company, and to the knowledge of the Company, any licensor, has complied with all applicable duty of candor requirements of the relevant patent authority with respect to such patents and patent applications.
To the knowledge of the Company, all licenses to which the Company and its Subsidiaries are a party relating to the Intellectual Property Rights are valid, subsisting, enforceable, and in good standing and each of the Company and its Subsidiaries
has, in all material respects, complied with its respective contractual obligations pursuant to all such licenses relating to the Intellectual Property Rights and has not committed any material breach thereof (declared or undeclared). The Company is
not a party to or bound by any options, licenses, or agreements with respect to the intellectual property rights of any other person or entity that are required to be disclosed in SEC Reports and that are not disclosed therein. None of the
Intellectual Property Rights used by the Company and its Subsidiaries has been obtained by them or is being used by them in violation of any material contractual obligations binding on the Company, its Subsidiaries or, to the knowledge of the
Company, any of their officers, directors or employees. Except as required to be set forth in the SEC Reports, (i)&nbsp;the Company and its Subsidiaries are not obligated to pay a material royalty, grant a license or provide other consideration to
any third party in connection with the Intellectual Property Rights and (ii)&nbsp;no third party, including any academic or governmental organization, possess material rights to the Intellectual Property Rights owned by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Compliance with Laws</U><I>. </I>The Company has not been advised, and has no reason to believe, that it and each of its
subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not reasonably be expected to have a
Material Adverse Effect. Except as described in the SEC Reports, each of the Company and its Subsidiaries: (i)&nbsp;is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing,
development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company
(&#147;<B><I>Applicable Laws</I></B>&#148;); (ii) has not, within the past five years, received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state,
local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required
by any such Applicable Laws (&#147;<B><I>Authorizations</I></B>&#148;); (iii) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such
Authorizations; (iv)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory
authority or third party alleging that any product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory
authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)&nbsp;has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory
authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is
considering such action; (vi)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or
Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent
submission); and (vii)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, &#147;dear doctor&#148; letter, or
other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the knowledge of the Company, no third party has initiated, conducted or intends to initiate any such notice
or action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Clinical Studies</U>. The studies, tests and preclinical and clinical trials conducted by or on behalf
of the Company or any of its Subsidiaries were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all
Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder; the descriptions of the results of such studies, tests and trials contained in the SEC
Reports are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except as disclosed in the SEC Reports, the Company is not aware of any studies, tests or trials, the results of
which the Company believes reasonably call into question the study results, test results, or trial results described or referred to in the SEC Reports when viewed in the context in which such results are described and the clinical state of
development; and, except as otherwise disclosed in the SEC Reports, since December&nbsp;31, 2019, the Company has not received any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory
authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>No Undisclosed Relationships</U>. No relationship, direct or indirect, exists between or among the Company or any of its
Subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its Subsidiaries, on the other, that is required by the Exchange Act to be described in the SEC Reports and that is not so
described in such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Company Act</U>. The Company is not and, after giving
effect to the transactions contemplated by this Agreement and the application of the proceeds therefrom, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148;
within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Taxes</U><I>.</I> The Company and its Subsidiaries have paid all material federal, state, local and foreign taxes and
filed all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in the SEC Reports, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company
or any of its Subsidiaries or any of their respective properties or assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Licenses or Permits</U><I>.</I> Except
as otherwise described in the SEC Reports, the Company and its Subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or
foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses, except where the failure to possess or make the same would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect; and except as described in the SEC Reports, neither the Company nor any of its Subsidiaries has received notice of any revocation or modification of any such license,
certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course that, individually or in the aggregate, if revoked, modified or failed to renew,
could reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>No Labor Disputes</U><I>.</I> No labor disturbance
by or dispute with employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the
employees of any of its or its Subsidiaries&#146; principal suppliers, contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Environmental Laws and Hazardous Materials</U><I>.</I> Except as described in the SEC Reports or except as would not,
singly or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the Company has not been advised, and has no reason to believe, that either the Company or any of its Subsidiaries is in violation of any applicable
federal, state, local or foreign statute, law, rule, regulation, ordinance, code or rule of common law or any binding and enforceable judicial or administrative interpretation thereof, including any binding and enforceable judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation,
laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum<I> </I>products (collectively, &#147;<B><I>Hazardous
Materials</I></B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B><I>Environmental Laws</I></B>&#148;), (ii) the Company has not been
advised, and has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
no reason to believe, that the Company and its Subsidiaries do not have all permits, authorizations and approvals required under any applicable Environmental Laws to operate the business of the
Company as currently conducted or are not each in compliance with their requirements, (iii)&nbsp;there are no pending or to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters,
claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its Subsidiaries and (iv)&nbsp;the Company has not been advised, and has no reason to believe, that
there are any events or circumstances that might reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or
agency, against the Company or any of its Subsidiaries relating to Hazardous Materials pursuant to any applicable Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Compliance with ERISA</U><I>.</I> The Company and its Subsidiaries and any &#147;employee benefit plan&#148; (as defined
in Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (collectively with the regulations and published interpretations thereunder, &#147;<B><I>ERISA</I></B>&#148;)) established or maintained by the Company, its
Subsidiaries or their ERISA Affiliates (as defined below) (&#147;<B><I>Company Benefit Plans</I></B>&#148;) are in compliance in all material respects with ERISA. &#147;<B><I>ERISA Affiliate</I></B>&#148; means, with respect to the Company or a
subsidiary, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Code of which the Company or such Subsidiary is a member. No Company Benefit Plan is a multiemployer plan (as defined in
Section&nbsp;4001(a)(3) and Section&nbsp;3(37) of ERISA) or a &#147;multiple employer plan&#148; (as defined in Section&nbsp;4063 or 4064 of ERISA). Furthermore, no Company Benefit Plan is a &#147;defined benefit plan&#148; as defined in
Section&nbsp;3(35) of ERISA or plan subject to Part 3, Subtitle B of Title I of ERISA, Section&nbsp;412 of the Code or Title IV of ERISA. None of the Company, its Subsidiaries or any of their ERISA Affiliates has incurred or reasonably expects to
incur any material liability under Sections 4975 or 4980B of the Code. Each Company Benefit Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act,
which would cause the loss of such qualification, except where such act or failure to act would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Disclosure Controls</U>. The Company and its Subsidiaries maintain an effective system of &#147;disclosure controls and
procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the
Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that
such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its Subsidiaries have carried out evaluations of the effectiveness of their
disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Accounting Controls</U><I>.</I> The Company and its Subsidiaries
maintain systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or
under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in
accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines
applicable thereto. Except as disclosed in the SEC Reports, there are no material weaknesses in the Company&#146;s internal controls. Based on the most recent evaluation of its disclosure controls and procedures, the Company is not aware of:
(i)&nbsp;any significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have materially adversely affected or are reasonably likely to materially adversely affect the
Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls
over financial reporting. Since the date of the last audited financial statements included in the SEC Reports, there has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>eXtensible Business
Reporting Language</U><I>.</I> The interactive data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Insurance</U><I>. </I>The Company and its Subsidiaries
have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are adequate to protect the Company and
its Subsidiaries and their respective businesses; and neither the Company nor any of its Subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to
be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers
as may be necessary to continue its business, except for such notices or <FONT STYLE="white-space:nowrap">non-renewal</FONT> that would not reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>No Unlawful Payments</U><I>.</I> Neither the Company nor any of its
Subsidiaries nor any director, officer or employee of the Company or any of its Subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its Subsidiaries has
(i)&nbsp;made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof) relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an
offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the FCPA or any applicable law
or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law (collectively, &#147;<B><I>Anti-Corruption Laws</I></B>&#148;); or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any
rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted, maintain and enforce, and
will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and Anti-Corruption Laws. Neither the Company nor any of its Subsidiaries will use, directly or indirectly, the
proceeds from the sale of the Securities hereunder in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Compliance with Anti-Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been
conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated
thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company and its Subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulation or guidelines issued,
administered or enforced by any governmental agency (collectively, the &#147;<B><I>Money Laundering Laws</I></B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>No Conflicts with Sanctions Laws</U><I>. </I>Neither the Company nor any of its Subsidiaries, nor any director, officer
or employee of the Company or any of its Subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its Subsidiaries is (i)&nbsp;currently the subject or the
target of any sanctions administered or enforced by the U.S. government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B><I>OFAC</I></B>&#148;), or the U.S. Department of State and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, His Majesty&#146;s Treasury, the United Nations
Security Council, or other relevant sanctions authority (collectively, &#147;<B><I>Sanctions</I></B>&#148;), (ii) located, organized, or resident in a country or territory that is the subject or target of Sanctions (a &#147;<B><I>Sanctioned
Jurisdiction</I></B>&#148;), and the Company will not directly or indirectly use the proceeds of the sale of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person, or in any country or territory, that, at the time of such funding or facilitation, is the subject or the target of Sanctions (ii)&nbsp;to fund or
facilitate any activities of or business in any Sanctioned Jurisdiction or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor
or otherwise) of Sanctions; neither the Company nor any of its Subsidiaries is engaged in, or has, at any time in the past five years, engaged in, any dealings or transactions with or involving any individual or entity that was or is, as applicable,
at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; the Company and its Subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued
compliance with Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>No Registration Rights</U>. Except as disclosed in the SEC Filings, no Person has the
right to require the Company or any of its Subsidiaries to effect the registration under the Securities Act of any securities of the Company or any Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>No Stabilization</U><I>.</I> Neither Company nor any of its affiliates has taken, directly or indirectly, any action
designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Sarbanes-Oxley Act Compliance</U>. There is and has been no failure on the part of the Company or, to the knowledge of
the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including
Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Cyber Security; Data
Protection</U>. The Company and its Subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, data and databases (collectively, &#147;<B><I>IT Systems</I></B>&#148;) are
adequate for, and operate and perform as required in connection with the operation of the business of the Company and the Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other&nbsp;corruptants, except where such inadequacy in, or failure to operate or perform, would not, reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company and its Subsidiaries have implemented
and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data
(including all personal, personally identifiable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
sensitive, confidential or regulated data (&#147;<B><I>Personal Data</I></B>&#148;)) used in connection with their businesses, and, except as disclosed in the SEC Reports, there have been no
breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or as would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company and its Subsidiaries or any of their properties or assets, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except where such
<FONT STYLE="white-space:nowrap">non-compliance</FONT> or failure to protect would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Acknowledgment Regarding Purchaser&#146;s Status</U>. The Company acknowledges and agrees that each Purchaser is acting
solely in the capacity of arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the
Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Purchaser&#146;s purchase of the Securities. The Company further represents to each Purchaser that the Company&#146;s decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the Company and its representatives and advisors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in
Section&nbsp;3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or
designated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents or any other agreements to be entered into by the Company and any Purchaser and certain other information provided on a confidential basis to the Purchaser that, in each case, will be timely publicly
disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided any Purchaser or their respective agents or counsel with any information that the Company believes constitutes material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the SEC Reports. The Company understands and confirms that each Purchaser will rely on the foregoing representation in effecting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purchases and sales of securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company, its business and the transactions
contemplated by the Transaction Documents, including the disclosure schedules to this Agreement, if any, is true and correct in all material respects. The Company acknowledges and agrees that no Purchaser either makes or has made any representations
or warranties with respect to the transactions contemplated by the Transaction Documents other than those specifically set forth in Section&nbsp;3.2 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>DTC Eligibility</U>. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated
Securities Transfer (FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations and Warranties of the Purchasers</U>. Each Purchaser hereby, on a several and not joint basis, represents and warrants
as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents to which such Purchaser is or will be a party and performance by such Purchaser of
the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which such
Purchaser is or will be a party has been or will be duly executed by the Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146;
rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable
law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Conflicts.</U> The execution, delivery and performance by the Purchaser of this Agreement, the other
Transaction Documents to which it is a party, and the consummation by the Purchaser of the transactions contemplated hereby and thereby will not (i)&nbsp;result in a violation of the organizational documents of the Purchaser, (ii)&nbsp;conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to
which the Purchaser is a party, or (iii)&nbsp;result in a violation by such Purchaser of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
applicable to such Purchaser, except in the case of clauses (ii)&nbsp;and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the ability of the Purchaser to perform its obligations under the Transaction Documents to which it is a party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities, and upon exercise of the Warrants, will
acquire the Warrant Shares issuable upon exercise of the Warrants, as principal for its own account, for investment purposes only, and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities (this representation and warranty not limiting such Purchaser&#146;s right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder
in the ordinary course of its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Purchaser Status</U>. At the time such Purchaser was offered the
Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i)&nbsp;a &#147;qualified institutional buyer&#148; as defined in Rule 144A(a) under the Securities Act or (ii)&nbsp;an
&#147;institutional account&#148; within the meaning of Rule 4512(c) of the Rules of FINRA. The Purchaser is not a registered broker-dealer registered under Section&nbsp;15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the
business of being a broker-dealer. The Purchaser is not affiliated with any broker-dealer registered under Section&nbsp;15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Experience of the Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of its decision to purchase Securities
pursuant to the Transaction Documents. The Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax
or investment advice. The Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. The Purchaser understands that the
Placement Agent has acted solely as the agent of the Company in this placement of the Securities and the Purchaser has not relied on the business or legal advice of the Placement Agent or any of their agents, counsel or Affiliates in making its
investment decision hereunder, and confirms that none of such Persons has made any representations or warranties to the Purchaser in connection with the transactions contemplated by the Transaction Documents. Such Purchaser is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Beneficial Ownership</U>. The purchase by the Purchaser of the
Securities issuable to it at the Closing will not result in the Purchaser (individually or together with any other Person with whom the Purchaser has identified, or will have identified, itself as part of a &#147;group&#148; in a public filing made
with the Commission involving the Company&#146;s securities) acquiring, or obtaining the right to acquire, in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes
that such Closing shall have occurred. The Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired, or
obtained the right to acquire, as a result of such Closing (when added to any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.999% of the outstanding shares of Common Stock or the voting power
of the Company on a post-transaction basis that assumes that each Closing shall have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Access to
Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i)&nbsp;the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information
about the Company, its Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such
additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. The Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided the Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agents nor any Affiliates
have made or make any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliates may have acquired <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to the Company which the
Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to the Purchaser, neither the Placement Agent nor any of its Affiliates have acted as a financial advisor or fiduciary to the Purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such
Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending
immediately prior to the execution hereof. Other than to other Persons party to this Agreement or to such Purchaser&#146;s representatives, including its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with the transactions contemplated by the Transaction Documents (including the existence and terms of the transactions contemplated hereby and thereby). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Certain Fees</U>. Except as set forth in the Prospectus Supplement,
no brokerage or finder&#146;s fees or commissions are or will be payable by the Company or the Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the
transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be
due in connection with the transactions contemplated by the Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>No Governmental Review</U>. The
Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)
<U>Regulation M</U>. The Purchaser is aware that the <FONT STYLE="white-space:nowrap">anti-manipulation</FONT> rules of Regulation M under the Exchange Act may apply to sales of Common Stock and other activities with respect to the Common Stock by
the Purchaser. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Residency</U>. The Purchaser&#146;s residence (if an individual) or offices in which its investment
decision with respect to the Securities was made (if an entity) are located at the address immediately below the Purchaser&#146;s name on its signature page hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Foreign Purchasers</U>. If the Purchaser is not a United States person (as defined by Section&nbsp;7701(a)(30) of the
Code): (i) the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction by such Purchaser in connection with any invitation to subscribe for the Securities or any use of this Agreement,
including (A)&nbsp;the legal requirements within its jurisdiction for the purchase of the Securities, (B)&nbsp;any foreign exchange restrictions applicable to such purchase or acquisition, (C)&nbsp;any government or other consents that may need to
be obtained, and (D)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities; and (ii)&nbsp;the Purchaser&#146;s subscription and payment for and continued
beneficial ownership of the Securities will not violate any applicable securities or other laws of the Purchaser&#146;s jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Placement Agent</U>. The Purchaser hereby acknowledges and agrees that it has independently evaluated the merits of its
decision to purchase the Securities, and that (i)&nbsp;the Placement Agent is acting solely as placement agent in connection with the execution, delivery and performance of the Transaction Documents and it is not acting as an underwriter or in any
other capacity and is not and shall not be construed as a fiduciary for the Purchaser, the Company or any other Person in connection with the execution, delivery and performance of the Transaction Documents, (ii)&nbsp;the Placement Agent has not
made and will not make any representation or warranty, whether express or implied, of any kind or character and have not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction Documents
and (iii)&nbsp;the Placement Agent will not have any responsibility with respect to (A)&nbsp;any representations, warranties or agreements made by any Person under or in connection with the execution, delivery and performance of the Transaction
Documents, or the execution, legality, validity or enforceability (with respect to any Person) thereof, or (B)&nbsp;the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER AGREEMENTS OF THE PARTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Warrant Shares. </U>If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to
cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the
Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify
the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant
Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall
use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Furnishing Information. </U>Until the earliest of the time that (i)&nbsp;no Purchaser owns Securities or (ii)&nbsp;the Warrants have
expired, the Company shall use commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the
Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Integration</U>. The
Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that
would require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Securities Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the Transaction Documents as exhibits thereto, with the Commission within the time required by
the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, <FONT STYLE="white-space:nowrap">non-public</FONT> information delivered to any of the
Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers,
directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall
be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each
Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with
prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency
or Trading Market, without the prior consent of such Purchaser (not to be unreasonably withheld), except (a)&nbsp;as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b)&nbsp;to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide such Purchaser with prior notice of such disclosure permitted under this clause (b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &#147;<B><I>Acquiring Person</I></B>&#148; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect
or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company
and the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Reservation and Listing of Securities.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the
Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents, including without limitation the exercise of the Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall, if applicable: (i)&nbsp;in the time and manner required by the Principal Trading Market, prepare and
file with such Trading Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on the date of such application, (ii)&nbsp;use commercially reasonable efforts to take all
steps necessary to cause such shares of Common Stock to be approved for listing or quotation on such Trading Market as soon as possible thereafter, (iii)&nbsp;provide to the Purchasers evidence of such listing or quotation and (iv)&nbsp;maintain the
listing or quotation of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading Market or another Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through DTC or another established clearing corporation, including, without limitation, by timely payment of fees to DTC or such other established clearing corporation in connection with such electronic transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Certain Transactions and Confidentiality</U>. Each Purchaser covenants that neither
it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company&#146;s securities during the period commencing with the execution of this Agreement
and ending on the date and such time that the transactions contemplated by this Agreement are first publicly announced pursuant to Section&nbsp;4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time
as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of the transactions contemplated hereby. The Company
expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to Section&nbsp;4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to
the Company or its Subsidiaries after the date and time of the filing of the Form <FONT STYLE="white-space:nowrap">8-K</FONT> as described in Section&nbsp;4.4. For the avoidance of doubt, this Section&nbsp;4.7 does not supersede or replace any
confidentiality obligations that such Purchaser may have to the Company pursuant to any prior confidentiality agreement entered between such Purchaser and the Company and such confidentiality agreement remains in effect in accordance with its terms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures
required of the Purchasers in order to exercise the Warrants. Without limiting the preceding sentence, no <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of any Purchaser to exercise its Warrants. The Company shall
honor exercise of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Company <FONT STYLE="white-space:nowrap">Lock-up</FONT></U>. For a period of 180 days after the date hereof (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating to, any shares of the Company that are substantially similar
to the Securities, including but not limited to any options or warrants to purchase shares of Securities or any securities convertible into or exercisable or exchangeable for, or that represent the right to receive, Securities or any such
substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Securities or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery of Securities or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than (A)&nbsp;the Company&#146;s sale of the Securities
hereunder, (B)&nbsp;the issuance of securities issued on a pro rata basis to all holders of a class of outstanding equity securities of the Company, (C)&nbsp;the issuance of restricted Common Stock, restricted stock units or options to acquire
Common Stock pursuant to the Company&#146;s employee benefit plans, qualified stock option plans or other employee compensation plans as such plans are in existence on the date hereof, including any increase approved by the Company&#146;s
stockholders, (D)&nbsp;issuances of Common Stock upon the exercise or settlement of options or restricted stock units that are outstanding as of the date hereof; (E)&nbsp;the purchase or sale of the Company&#146;s securities pursuant to a plan,
contract or instruction, if any, that satisfies all of the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1(c)(1)(i)(B)</FONT> that was in effect prior to the date hereof; or (F)&nbsp;the issuance of securities which may be sold, on an <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> basis, only to unaffiliated service providers, vendors, customers, strategic partners and collaborators pursuant to a collaboration, licensing agreement, strategic alliance, lease, manufacturing or
distribution agreement or similar transaction in connection with the acquisition of assets, technologies or other entities. The Company also agrees that during such period, the Company will not file any registration statement, preliminary prospectus
or prospectus, or any amendment or supplement thereto, under the Securities Act for any such transaction or which registers, or offers for sale, Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, except
for a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to employee benefit plans. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Termination</U>. This Agreement may be terminated by the Company or each Purchaser if the Closing has not been consummated on or before the fifth Trading Day following the date hereof; <I>provided</I>, <I>however</I>, that (A)&nbsp;no such
termination will (i)&nbsp;affect the right of any party to sue for any breach by any other party (or parties), (ii) relieve any party from liability for any willful misconduct or breach of this Agreement, fraud or knowing misrepresentation or
omission, and (B)&nbsp;the provisions of this Section&nbsp;5.1 (termination) and Section&nbsp;5.2 (fees and expenses) shall remain in full force and effect and survive any termination of this Agreement. In the event of termination, the Company shall
promptly return the Purchaser&#146;s Subscription Amount to each respective Purchaser by wire transfer of United States dollars in immediately available funds to the account specified by each Purchaser, and any book entries for the Shares and
Warrants shall be deemed cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the
contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
Agreement. Notwithstanding the previous sentence, the Company shall pay all reasonable and documented fees and expenses incurred in connection with the Transaction Documents, including any Transfer Agent fees (including, without limitation, any fees
required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company and any exercise notice delivered by any Purchaser, if applicable), stamp taxes and other taxes and duties levied in
connection with the delivery of any Securities to the Purchasers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and
schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any and all notices or other communications
or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or email attachment at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day
after the time of transmission, if such notice or communication is delivered via facsimile or email attachment at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as set forth on the signature pages attached hereto on a
day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual
receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers and, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; <I>provided</I>, that any waiver, modification, supplement or amendment of
Article II &#150; related to the purchase and sale, including price, Sections 4.1(c) (legend removal assistance), 4.3 (disclosures), 4.5 (reservation and listing of securities), 5.1 (termination), 5.5 (amendments) and 5.15 (remedies) shall require a
written instrument signed by the Company and each Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon all Purchasers and any subsequent holder of Securities and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit
of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or
all of its rights under this Agreement to any Person to whom the Purchaser assigns or transfers any Securities, <I>provided</I>, that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the
Transaction Documents that apply to the &#147;Purchaser.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the
third party beneficiaries of the representations and warranties of the Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended for the benefit of the parties hereto and
their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. All questions concerning the construction, validity, enforcement
and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all
legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper
or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such
Action or Proceeding shall be reimbursed by the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Survival</U>. Subject to the applicable statute of limitations, the representations and warranties
contained herein hereto shall survive the Closing and the delivery of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Execution</U>. This Agreement may be
executed in counterparts, each of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the
parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;.pdf&#148; format data file, such signature shall create a
valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#147;.pdf&#148; signature page were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its
related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights; <I>provided</I>, <I>however</I>, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#146;s right to acquire such shares pursuant to such Purchaser&#146;s Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <U>Replacement of Securities</U>. If any
certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and
substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of
obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.16 <U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or
equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.17 <U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.18 <U>Construction</U>. The parties agree that each of them and/or their respective
counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the
interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.19
<U>WAIVER OF JURY TRIAL</U><B>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.20 <U>Exculpation of the Placement Agents</U>. Each party
hereto agrees, for the express benefit of the Placement Agents, their respective affiliates and representatives, that, in connection with the Transaction Documents and the transactions contemplated thereby: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither the Placement Agents nor any of their respective affiliates or any of their representatives (i)&nbsp;shall be
liable for any improper payment made in accordance with the information provided by the Company; (ii)&nbsp;make any representation or warranty, or have any responsibilities as to the validity, accuracy, value or genuineness of any information,
certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or the other Transaction Documents or in connection with any of the transactions contemplated by this Agreement or the other Transaction Documents,
including any offering or marketing materials; or (iii)&nbsp;shall be liable (x)&nbsp;for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers
conferred upon them by this Agreement or any other Transaction Document or (y)&nbsp;for anything which any of them may do or refrain from doing in connection with this Agreement or any other Transaction Document, except for such party&#146;s own
gross negligence, willful misconduct or bad faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Placement Agents, their respective affiliates and
representatives shall be entitled to rely on, and shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of the Placement Agents, their respective affiliates and
representatives, by or on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[remainder of page intentionally left blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SANGAMO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Willoughby</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Notice: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 Canal Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richmond, California 94084 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Scott Willoughby </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [*] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3 Embarcadero Center, 20th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California 94111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chad Mills, Courtney
Tygesson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to the
Securities Purchase Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have caused this Securities Purchase Agreement to
be duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Holder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address for Notice to Purchaser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Subscription Amount:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shares of Common Stock:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744; 4.99% or &#9744; 9.99% or &#9744; 14.99% or &#9744; 19.99% or &#9744; N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Purchase Price of Securities:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery Instructions, if different from above: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Street: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">City/State/Zip: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone No.: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to the
Securities Purchase Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Common Stock Warrant </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[attached] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">_____________, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>ARCLAYS</SMALL>
C<SMALL>APITAL</SMALL> I<SMALL>NC</SMALL>. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ANTOR</SMALL> F<SMALL>ITZGERALD</SMALL>&nbsp;&amp; C<SMALL>O</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Placement Agents </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as Placement Agents, propose to enter into an placement agent agreement (the &#147;<B>Placement Agent
Agreement</B>&#148;) with Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the offering (the &#147;<B>Offering</B>&#148;) by the Company, of common stock, par value $0.01 per share, of the Company
(the &#147;<B>Common Stock</B>&#148;) and warrants to purchase Common Stock (the &#147;<B>Warrants</B>&#148; and, together with the Common Stock, the &#147;<B>Securities</B>&#148;). Capitalized terms used herein and not otherwise defined shall have
the meanings set forth in the Placement Agent Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce Barclays Capital Inc. and Cantor Fitzgerald&nbsp;&amp; Co.
(each, a &#147;<B>Placement Agent</B>&#148; and together, the &#147;<B>Placement Agents</B>&#148;) to act as Placement Agents for the Offering, the undersigned hereby agrees that, without the prior written consent of the Placement Agents, the
undersigned will not, during the period ending 90 days after the date hereof (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned now or hereafter by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission
(such shares or securities, the &#147;<B>Beneficially Owned Shares</B>&#148;) and securities which may be issued upon exercise of a stock option or warrant), (2) engage in any hedging or other transaction or arrangement (including, without
limitation, any short sale or the purchase or sale of, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which
reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part,
directly or indirectly, of any Beneficially Owned Shares, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise (any such sale, loan, pledge
or other disposition, or transfer of economic consequences, a &#147;<B>Transfer</B>&#148;), (3) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock, or (4)&nbsp;otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (1), (2) or (3)&nbsp;above, in each case other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers of Beneficially Owned Shares, Common Stock or securities convertible into or exercisable or exchangeable for Common Stock
(i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (iii)&nbsp;to any &#147;affiliate&#148; (as that term is defined in Rule 405 under the
Securities Act of 1933, as amended) of the undersigned or (iv)&nbsp;by will or intestacy to the undersigned&#146;s legal representative, heir or legatee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) pursuant to any contract, instruction or plan complying with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Securities
Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that has been entered into by the undersigned prior to the date of this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the acquisition or exercise of any stock option issued pursuant to the Company&#146;s existing stock option plan, including any exercise
effected by the delivery of shares of Common Stock held by the undersigned; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any conversion of restricted stock units into shares of
Common Stock as provided in the applicable restricted stock unit issuance agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any transfer of shares of Common Stock to the
Company in connection with the undersigned&#146;s tax withholding obligation upon issuance of such shares pursuant to the applicable restricted stock unit issuance agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any sale or transfer of shares of Common Stock (including in open market transactions through a broker) to satisfy the undersigned&#146;s
tax withholding obligations in connection with the vesting of equity awards pursuant to the Company&#146;s equity compensation plans or arrangements, which are described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, and which equity awards vest during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) pursuant to a sale or an
offer to purchase 100% of the outstanding Common Stock, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties resulting in a Change of Control (as defined below) and approved by the Company&#146;s board
of directors, provided that, in the event that such a Change of Control is not completed, the undersigned&#146;s shares shall remain subject to the restrictions contained in this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement and title to
the undersigned&#146;s shares shall remain with the undersigned; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) the establishment of a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Common Stock, provided that such plan does not provide for the transfer and sale of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period, and provided further that, except as required by applicable securities laws, no public announcement of the establishment or existence of such plan, and no filing with the Securities and Exchange Commission or any other regulatory authority
in respect thereof or for transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall be required, and no announcement or filing shall be made voluntarily by the undersigned, the Company or any other
person prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any transfer or distribution
pursuant to clause (a)&nbsp;above, each donee or distributee or transferee shall execute and deliver to the Placement Agents a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter for the balance of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in the form of this paragraph and, pursuant to clauses (a)(ii) through (iv)&nbsp;above, no filing by any party (donor, donee, distributor, distributee, transferor or transferee) under the
Exchange Act, or other public announcement reporting a reduction in the beneficial ownership shall be required or shall be made voluntarily in connection with such transfer or distribution. In the case of any transfer or distribution pursuant to
clause (a)(i) above, it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement
reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement
shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. For the avoidance of doubt, any shares of Common Stock received by the undersigned upon the exercise of a stock option or conversion of restricted stock
units as described in foregoing clauses (c)&nbsp;and (d) shall be subject to the restrictions under this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In the case of any sale or transfer pursuant to clause (f)&nbsp;above, any public
filing, report or announcement of any such sale or transfer shall disclose that the sale or transfer was for the purpose of covering the withholding taxes payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement, (1) &#147;<B>immediate family</B>&#148; shall mean any
spouse, domestic partner, lineal descendant (including adopted children), father, mother, brother or sister of the transferor and (2) &#147;<B>Change of Control</B>&#148; shall mean the transfer (whether by tender offer, merger, consolidation or
other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an Investor pursuant to the Offering), of the Company&#146;s voting securities if, after such transfer, such
person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become,
currently a party to any agreement or arrangement that provides for, is designed to or reasonably could be expected to lead to or result in any Transfer prohibited by this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the
registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;the Placement Agent Agreement does not become effective by March&nbsp;22, 2024, (ii) the
Placement Agent Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, or (iii)&nbsp;the Company notifies the Placement
Agents in writing that it will not be proceeding with the Offering prior to the execution of the Placement Agent Agreement, the undersigned shall be released from, all obligations under this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.
The undersigned understands that the Placement Agents are entering into the Placement Agent Agreement and proceeding with the Offering in reliance upon this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement and any claim, controversy or dispute arising under or related to this <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Lock-Up Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[attached] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>d816036dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SANGAMO THERAPEUTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24,761,905 Shares of Common Stock par value $0.01 per share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase up to 3,809,523 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Warrants to Purchase 28,571,428 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Placement Agent Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;21, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BARCLAYS CAPITAL INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANTOR FITZGERALD&nbsp;&amp; CO. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8194;As Placement Agents </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald&nbsp;&amp; Co.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street, 6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell directly to various investors
(each, an &#147;<B>Investor</B>&#148; and collectively, the &#147;<B>Investors</B>&#148;), pursuant to the terms of this Placement Agent Agreement (this &#147;<B>Agreement</B>&#148;) and the Securities Purchase Agreement in the form of <U>Exhibit
D</U> attached hereto (the &#147;<B>Securities Purchase Agreement</B>&#148;) entered into with such Investors, an aggregate of 24,761,905 shares of common stock, par value $0.01 per share (the &#147;<B>Common Stock</B>&#148;), of the Company (the
&#147;<B>Shares</B>&#148;), <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to an aggregate of 3,809,523 shares of Common Stock at an exercise price of $0.001 per share (the
&#147;<B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#148;) and warrants to purchase an aggregate of 28,571,428 shares of Common Stock of the Company (the &#147;<B>Warrants</B>&#148;). The Common Stock issuable upon the exercise
of the Warrants are referred to herein as the &#147;<B>Warrant Shares</B>&#148; and the Common Stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are referred to herein as the &#147;<B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</B>.&#148; The Shares, the Warrants, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and the Warrant Shares
are herein referred to as the &#147;<B>Securities</B>.&#148; The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Securities are referred to herein as the &#147;<B>Stock</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the Placement Agents concerning the purchase and sale of the Securities to the Investors, as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), a registration statement (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-255792),</FONT> including a prospectus, relating to the Securities. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430B or
430C under the Securities Act to be part of the registration statement at the time of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness (&#147;<B>Rule 430 Information</B>&#148;), is referred to herein as the &#147;<B>Registration Statement</B>&#148;; and as used herein, the term &#147;<B>Prospectus</B>&#148; means
the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. If the Company has filed an abbreviated registration
statement pursuant to Rule 462(b) under the Securities Act (the &#147;<B>Rule 462 Registration Statement</B>&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration
Statement. Any reference in this Agreement to the Registration Statement or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of the Prospectus, as the case may be, and any reference to &#147;amend&#148;, &#147;amendment&#148; or
&#147;supplement&#148; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration Statement (including Post-Effective Amendment No.&nbsp;1 thereto filed with
the Commission on February&nbsp;22, 2023 and Post-Effective Amendment No.&nbsp;2 thereto filed with the Commission on February&nbsp;23, 2023), that has become or been declared effective, any prospectus supplement relating to the Securities filed
with the Commission pursuant to Rule 424(b) under the Securities Act and any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the
&#147;<B>Exchange Act</B>&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing
information set forth on <U>Annex A</U>, the &#147;<B>Pricing Disclosure Package</B>&#148;): each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on <U>Annex A</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Time</B>&#148; means 11:00 P.M., New York City time, on March&nbsp;21, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Sale, Purchase, Delivery and Payment of the Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Placement Agents shall be the exclusive Placement Agents in connection with the offering and sale by the Company of the Securities
from time to time pursuant to the Registration Statement (such offering, the &#147;<B>Offering</B>&#148;), to be subject to market conditions and negotiations between the Company and the prospective Investors. The Placement Agents will act on a
reasonable efforts basis, and the Company agrees and acknowledges that there is no guarantee of the successful placement of the Securities, or a portion thereof, in a prospective Offering. Under no circumstances will the Placement Agents or any of
their affiliates be obligated to underwrite or purchase any of the Securities for its own account or otherwise provide any financing. The Placement Agents shall have no authority to bind the Company with respect to any prospective offer to purchase
Securities, and the Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof, payment of the purchase price for, and delivery of, the
Securities shall be made at the Closing (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Until the Closing Date or earlier upon termination of this Agreement
pursuant to Section&nbsp;9, the Company shall not, without the prior written consent of the Placement Agents, solicit or accept offers to purchase the Securities otherwise than through the Placement Agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Subject to the provisions of this Section&nbsp;2, offers for the purchase of Securities
may be solicited by the Placement Agents, as agents for the Company at such times and in such amounts as the Placement Agents deem advisable. The Placement Agents shall communicate to the Company, orally or in writing, each reasonable offer to
purchase Securities received by it as agents of the Company. The company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. The Placement Agents shall have the right, in their
discretion reasonably exercised, without notice to the Company, to reject any offer to purchase Securities received by it, in whole or in part, and any such rejection shall not be deemed a breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The purchase of Securities by the Investors shall be evidenced by the execution of a Securities Purchase Agreement in form and substance
consistent with <U>Exhibit D</U> hereto by each of the Investors and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) As compensation for services rendered, on the
Closing Date, the Company shall pay to the Placement Agents by wire transfer of immediately available funds to an account or accounts designated by the Placement Agents, an aggregate amount equal to 6% of the gross proceeds received by the Company
(the &#147;<B>Placement Fee</B>&#148;) from the sale of the Securities on the Closing Date that were solicited by the Placement Agents. The Placement Agents may retain other brokers or dealers to act as
<FONT STYLE="white-space:nowrap">sub-agents</FONT> or selected-dealers on their behalf in connection with the Offering, the fees of which shall be paid out of the Placement Fee paid to the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) No Securities which the Company has agreed to sell pursuant to this Agreement and the Securities Purchase Agreement shall be deemed to
have been purchased and paid for, or sold by the Company, until such Securities shall have been delivered to the Investor thereof against payment by such Investor. If the Company shall default in its obligations to deliver such Securities to an
Investor whose offer it has accepted, the Company shall indemnify and hold the Placement Agents harmless against any loss, claim, damage or expense arising from or as a result of such default by the Company in accordance with the procedures set
forth in Section&nbsp;7 herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The time and date of closing (the &#147;<B>Closing</B>&#148;) and delivery of the documents required
to be delivered to the Placement Agents pursuant to Section&nbsp;6 hereof shall be at 10:00 A.M., New York time, on March&nbsp;26, 2024 (the &#147;<B>Closing Date</B>&#148;) at the office of White&nbsp;&amp; Case LLP, 1221 Avenue of the Americas,
New York, New York 10020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Placement
Agent that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and
as of the Closing Date and will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Placement Agent furnished to the Company in writing by such
Placement Agent expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Placement Agent consists of the information described as such in Section&nbsp;7(b) hereof. No
statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been
omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement and the Prospectus, the Company (including its agents and representatives, other than the Placement Agents in their capacity as such) has not prepared, used, authorized, approved or referred to and will not prepare, use, authorize, approve
or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and
representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;<B>Issuer Free Writing Prospectus</B>&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the
Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Placement Agents. Each such Issuer Free
Writing Prospectus complied in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with
the information contained in the Registration Statement or the Pricing Disclosure Package, and did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation and warranty with respect to any statements or omissions made in each such Issuer Free
Writing Prospectus in reliance upon and in conformity with information relating to any Placement Agent furnished to the Company in writing by such Placement Agent expressly for use in such Issuer Free Writing Prospectus, it being understood and
agreed that the only such information furnished by any Placement Agent consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Registration Statement and Prospectus.</I> The Registration Statement in respect of the Securities has been filed with
the Commission; the Registration Statement was declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to
Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Securities has been initiated or threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective
amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will comply in
all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Placement Agent furnished to the Company
in writing by such Placement Agent expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Placement Agent consists of
the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Incorporated Documents.</I> The documents
incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such
documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such
documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Financial Statements.</I>
The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all
material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates
indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States applied on a
consistent basis throughout the periods covered thereby, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the
other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and
presents fairly the information shown thereby. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Prospectus or the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options
and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of
the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a
prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the
Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation,
direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and
its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, including a health epidemic or pandemic outbreak of infectious disease (including without limitation, a further outbreak or escalation of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or any related/mutated form of <FONT STYLE="white-space:nowrap">COVID-19),</FONT> whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or
arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Organization and Good Standing.</I> The Company and each of its
subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position,
stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement, the Securities Purchase Agreement, the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants (a &#147;<B>Material Adverse Effect</B>&#148;). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the
subsidiaries listed in Exhibit 21 to the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Capitalization.</I> The Company has an authorized
capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by the Pricing Disclosure Package and the Prospectus,
there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other
equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or
exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the
Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> except as otherwise described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and are owned directly or indirectly by the Company, free and clear of any material
lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
<I>Stock Options. </I>With respect to the stock options (the &#147;<B>Stock Options</B>&#148;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;<B>Company Stock Plans</B>&#148;), (i) each Stock
Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code so qualifies, (ii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other
applicable laws and regulatory rules or requirements, including the rules of The Nasdaq Global Select Market (the &#147;<B>Nasdaq Market</B>&#148;) and any other exchange on which Company securities are traded, and (iii)&nbsp;each such grant was
properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable
laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement,
the Securities Purchase Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants and to perform its obligations hereunder and thereunder; and all action required to be taken for the due and proper authorization,
execution and delivery by it of this Agreement, the Securities Purchase Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants and the consummation by it of the transactions contemplated hereby has been duly and
validly taken. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Agreements. </I>Each of this Agreement and the Securities Purchase
Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Securities Purchase Agreement</I>. The
Company has entered into a Securities Purchase Agreement with the Investors that contains representations, warranties and covenants of the Company and the Investors. Such representations, warranties and covenants shall be relied upon by the
Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>The Securities. </I>The Shares to be issued and sold by the Company hereunder have been duly
authorized and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material respects to the descriptions
thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in the form
attached hereto as <U>Exhibit B</U> have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this Agreement, will constitute valid and legally binding agreements of the Company, enforceable against
the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by equitable principles relating to enforceability. The Warrants
in the form attached hereto as <U>Exhibit C</U> have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this Agreement and the Securities Purchase Agreement, will constitute valid and legally
binding agreements of the Company, enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by
equitable principles relating to enforceability. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares have been duly authorized and reserved for issuance pursuant to the terms of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and when the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares are issued by the Company upon valid exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants, such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and not subject to any preemptive rights, rights of first refusal or
similar rights. The Warrant Shares have been duly authorized and reserved for issuance pursuant to the terms of the Warrants, and when the Warrant Shares are issued by the Company upon valid exercise of the Warrants, such Warrant Shares will be
validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and not subject to any preemptive rights, rights of first refusal or similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Stock Exchange Listing</I>. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and are
listed on the Nasdaq Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Market,
nor has the Company received any notification that the Commission or the Nasdaq Market is contemplating terminating such registration or listing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>No Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or
(iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation
that would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Statements in the Registration
Statement</I>. The statements set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the caption &#147;Description of Capital Stock&#148;, insofar as they purport to constitute a summary of the terms of the
Common Stock, under the caption &#147;Material U.S. Federal Income Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#148; and &#147;Plan of Distribution&#148;, insofar as they purport to describe the provisions of the
laws and documents referred to therein, are accurate, complete and fair in all material respects. The statements made in or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the captions
&#147;Business&#151;Therapeutic Product Candidates in Development&#151;Current Partnerships and Collaborations,&#148; &#147;Business&#151;Intellectual Property,&#148; &#147;Business&#151;Government Regulation&#148; and &#147;Risk Factors&#151;Risks
Relating to our Intellectual Property,&#148; insofar as they purport to constitute summaries of the terms of statutes, rules or regulations, legal or governmental proceedings or contracts and other documents, constitute accurate summaries of the
terms of such statutes, rules and regulations, legal and governmental proceedings and contracts and other documents in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the Securities Purchase
Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants, the issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement, the Securities Purchase Agreement, the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Warrants or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default
under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any
violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment,
order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not,
individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Consents Required.</I> No consent, approval,
authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the Securities Purchase
Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Warrants, the issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement, the Securities Purchase Agreement, the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be
required by the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) and under applicable state securities laws in connection with the placement of the Securities by the Placement Agents and the purchase of the Securities by the
Investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Legal Proceedings.</I> Except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is or may be a party or to which any
property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; no
such investigations, actions, suits or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending legal, governmental
or regulatory actions, suits or proceedings that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the
Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Independent Auditors</I>. Ernst&nbsp;&amp; Young LLP, who have audited certain financial statements of the Company and
its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United
States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Title to Real and Personal Property</I>. The Company and its
subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective
businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of
such property by the Company and its subsidiaries or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Intellectual Property</I>. To the Company&#146;s knowledge with respect to patents, patent applications, trade and
service marks, trade and service mark registrations, and trade names only, the Company and its subsidiaries own, possess, or license, and otherwise have legally enforceable rights to all patents, patent applications, trade and service marks, trade
and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, and <FONT STYLE="white-space:nowrap">know-how,</FONT> except with regard to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software provided by third parties, (collectively, the &#147;<B>Intellectual Property Rights</B>&#148;) necessary for the conduct of the Company&#146;s
business as now conducted or, to the knowledge of the Company, as proposed in the Pricing Disclosure Package and the Prospectus to be conducted. Except as disclosed in the Pricing Disclosure Package and the Prospectus, (i)&nbsp;to the knowledge of
the Company, there are no rights of third parties to any such Intellectual Property Rights that conflict with the Company&#146;s right to own, possess or license, as applicable, such Intellectual Property Rights; (ii)&nbsp;the Company is not aware
of any material infringement by third parties of any such Intellectual Property Rights; (iii)&nbsp;there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others challenging the Company&#146;s rights
in or to own, possess and license such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (iv)&nbsp;there is no pending, or to the knowledge of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company threatened, action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would
form a reasonable basis for any such claim, except for any such action, suit, proceeding or claim that would not have a Material Adverse Effect; (v)&nbsp;there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or
claim by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any such
claim, except for any such action, suit, proceeding or claim that would not have a Material Adverse Effect; (vi)&nbsp;to the knowledge of the Company, there is no U.S. patent or published U.S. patent application (other than U.S. patents or U.S.
patent applications of the Company) which contains claims that dominate or may dominate any Intellectual Property Rights described in the Pricing Disclosure Package and the Prospectus as being owned by or licensed to the Company or that interferes
with the issued or pending claims of any such Intellectual Property Rights, except for such claims and interferences that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; (vii)&nbsp;there is no
prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or any U.S. patent application held by the Company unpatentable which has not been disclosed to the U.S. Patent and Trademark Office, and
(viii)&nbsp;to the knowledge of the Company, all pertinent prior art references known to the Company or its counsel during the prosecution of<I> </I>the patents and patent applications comprising the Intellectual Property Rights were disclosed to
the relevant patent authority and, to the knowledge of the Company, neither such counsel nor the Company nor any licensor made any misrepresentation to, or concealed any material fact from, the relevant patent authority during such prosecution and
the Company, and to the knowledge of the Company, any licensor, has complied with all applicable duty of candor requirements of the relevant patent authority with respect to such patents and patent applications. To the knowledge of the Company, all
licenses to which the Company and its subsidiaries is a party relating to the Intellectual Property Rights are valid, subsisting, enforceable, and in good standing and each of the Company and its subsidiaries has, in all material respects, complied
with its respective contractual obligations pursuant to all such licenses relating to the Intellectual Property Rights and has not committed any material breach thereof (declared or undeclared). The Company is not a party to or bound by any options,
licenses, or agreements with respect to the intellectual property rights of any other person or entity that are required to be disclosed in Pricing Disclosure Package and the Prospectus and that are not disclosed therein. None of the Intellectual
Property Rights used by the Company and its subsidiaries has been obtained by them or is being used by them in violation of any material contractual obligations binding on the Company, its subsidiaries or, to the knowledge of the Company, any of
their officers, directors, or employees. Except as required to be set forth in the Pricing Disclosure Package and the Prospectus, (i)&nbsp;the Company and its subsidiaries are not obligated to pay a material royalty, grant a license or provide other
consideration to any third party in connection with the Intellectual Property Rights and (ii)&nbsp;no third party, including any academic or governmental organization, possess material rights to the Intellectual Property Rights owned by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Compliance with Laws. </I>The Company has not been advised, and has no reason to believe, that it and each of its
subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not result in a Material Adverse
Effect. Except as described in the Pricing Disclosure Package, each of the Company and its subsidiaries: (A)&nbsp;is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing,
development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
product under development, manufactured or distributed by the Company (&#147;<B>Applicable Laws</B>&#148;); (B) has not, within the past five years, received any FDA Form 483, notice of adverse
finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) or any other federal, state, local or foreign governmental or regulatory authority alleging or
asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;<B>Authorizations</B>&#148;);
(C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D)&nbsp;has not received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in
material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; (E)&nbsp;has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or
revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (F)&nbsp;has filed, obtained, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted, or
issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, &#147;dear doctor&#148; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any
alleged product defect or violation and, to the Company&#146;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Clinical Studies</I>. The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company or
any of its subsidiaries were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and
Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, &#147;<B>FFDCA</B>&#148;); the descriptions of the results of such studies, tests and trials
contained in the Registration Statement and the Pricing Disclosure Package are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except as disclosed in the Pricing Disclosure
Package, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study results, test results, or trial results described or referred to in the Registration Statement and
the Pricing Disclosure Package when viewed in the context in which such results are described and the clinical state of development; and, except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
since December&nbsp;31, 2018, the Company has not received any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification
of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>No Undisclosed Relationships</I>. No relationship, direct or
indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities
Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Securities and
the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an
&#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<B>Investment Company Act</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Taxes.</I> The Company and its subsidiaries have paid all material federal, state, local and foreign taxes and filed
all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or could
reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Licenses or Permits.</I> Except as otherwise described in each of the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign
governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses, except where the failure to possess or make the same would not, individually or in the
aggregate, have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or
modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course that, individually or in the aggregate, if
revoked, modified or failed to renew, could result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>No Labor Disputes.</I> No labor
disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute
with, the employees of any of its or its subsidiaries&#146; principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Environmental Laws and Hazardous Materials.</I> Except as described in the Pricing Disclosure Package and the
Prospectus or except as would not, singly or in the aggregate, result in a Material Adverse Effect, (i)&nbsp;the Company has not been advised, and has no reason to believe, that either the Company or any of its subsidiaries is in violation of any
applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code or rule of common law or any binding and enforceable judicial or administrative interpretation thereof, including any binding and enforceable judicial or
administrative order, consent, decree or judgment, relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without
limitation, laws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum<I> </I>products
(collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (ii) the
Company has not been advised, and has no reason to believe, that the Company and its subsidiaries do not have all permits, authorizations and approvals required under any applicable Environmental Laws to operate the business of the Company as
currently conducted or are not each in compliance with their requirements, (iii)&nbsp;there are no pending or to the Company&#146;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens,
notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv)&nbsp;the Company has not been advised, and has no reason to believe, that there are any
events or circumstances that might reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency,
against the Company or any of its subsidiaries relating to Hazardous Materials pursuant to any applicable Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Compliance with ERISA.</I> The Company and its subsidiaries and any &#147;<B>employee benefit plan</B>&#148; (as
defined in Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (collectively with the regulations and published interpretations thereunder, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its
subsidiaries or their &#147;<B>ERISA Affiliates</B>&#148; (as defined below) (&#147;<B>Company Benefit Plans</B>&#148;) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company or a
subsidiary, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of
which the Company or such subsidiary is a member. No Company Benefit Plan is a multiemployer plan (as defined in Section&nbsp;4001(a)(3) and Section&nbsp;3(37) of ERISA) or a &#147;multiple employer plan&#148; (as defined in Section&nbsp;4063 or
4064 of ERISA). Furthermore, no Company Benefit Plan is a &#147;defined benefit plan&#148; as defined in Section&nbsp;3(35) of ERISA or plan subject to Part 3, Subtitle B of Title I of ERISA, Section&nbsp;412 of the Code or Title IV of ERISA. None
of the Company, its subsidiaries or any of their ERISA Affiliates has incurred or reasonably expects to incur any material liability under Sections 4975 or 4980B of the Code. Each Company Benefit Plan that is intended to be qualified under
Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification, except where such act or failure to act would not, individually or in the aggregate,
result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Disclosure Controls</I>. The Company and its subsidiaries maintain an
effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms,
including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have
carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the
supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset
accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in
all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material
weaknesses in the Company&#146;s internal controls. Based on the most recent evaluation of its disclosure controls and procedures, the Company is not aware of: (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation
of internal controls over financial reporting which have materially adversely affected or are reasonably likely to materially adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and
(ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. Since the date of the last audited financial statements included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>eXtensible Business
Reporting Language.</I> The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in
accordance with the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Critical Accounting Policies</I>.
The section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; set forth or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
accurately and fully describes (i)&nbsp;the accounting policies that the Company believes are the most important in the portrayal of the Company&#146;s financial condition and results of operations and that require management&#146;s most difficult,
subject or complex judgments (&#147;<B>Critical Accounting Policies</B>&#148;); (ii) the judgments and uncertainties affecting the application of Critical Accounting Policies; and (iii)&nbsp;the likelihood that materially different amounts would be
reported under different conditions or using different assumptions and an explanation thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Insurance. </I>The
Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are
adequate to protect the Company and its subsidiaries and their respective businesses; and neither the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in
order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be
necessary to continue its business, except for such notices or <FONT STYLE="white-space:nowrap">non-renewal</FONT> that would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director, officer or employee of the
Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;made, offered, promised or authorized any
unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof) relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or
indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on
behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law (collectively, &#147;<B>Anti-Corruption Laws</B>&#148;); or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate,
payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted, maintain and enforce, and will
continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and Anti-Corruption Laws. Neither the Company nor any of its subsidiaries will use, directly or indirectly, the
proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been
conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated
thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulation or guidelines issued,
administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the
Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, nor any director, officer or
employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i)&nbsp;currently the subject or the
target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;), or the U.S. Department of State and including, without limitation, the designation as a
&#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, His Majesty&#146;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), (ii)
located, organized, or resident in a country or territory that is the subject or target of Sanctions (a &#147;<B>Sanctioned Jurisdiction</B>&#148;), and the Company will not directly or indirectly use the proceeds of the offering of the Securities
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person, or in any country or territory,
that, at the time of such funding or facilitation, is the subject or the target of Sanctions (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Jurisdiction or (iii)&nbsp;in any other manner that will result in a
violation by any person (including any person participating in the transaction, whether as placement agent, advisor, investor or otherwise) of Sanctions; neither the Company nor any of its subsidiaries is engaged in, or has, at any time in the past
five years, engaged in, any dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; the
Company and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly,
under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest, from repaying to the
Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Placement Agent for a brokerage commission, finder&#146;s fee or like payment in connection with
the offering and sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Registration Rights</I>. Except as disclosed in the Pricing Disclosure
Package, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>No Stabilization.</I> Neither Company nor any of its affiliates has taken, directly or indirectly, any
action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed
other than in good faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Statistical and Market Data.</I> Nothing has come to the attention
of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from
sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Sarbanes-Oxley Act Compliance</I>. There is and
has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the
rules and regulations promulgated in connection therewith (the &#147;<B>Sarbanes-Oxley Act</B>&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>No Outstanding Loans or Other Extensions of Credit</I>. Since the adoption of Section&nbsp;13(k) of the Exchange Act,
neither the Company nor any of its subsidiaries has extended or maintained credit, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent
thereof) of the Company and/or such subsidiary except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is
not an &#147;ineligible issuer,&#148; as such term is defined in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>No
Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating
organization&#148;, as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Cyber Security; Data
Protection</I>. The Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, data and databases (collectively, &#147;<B>IT Systems</B>&#148;) are
adequate for, and operate and perform as required in connection with the operation of the business of the Company and the subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other&nbsp;corruptants, except where such inadequacy in, or failure to operate or perform, would not, individually or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries have implemented and maintained commercially
reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally
identifiable, sensitive, confidential or regulated data (&#147;<B>Personal Data</B>&#148;)) used in connection with their businesses, and, except as disclosed in the Pricing Disclosure Package, there have been no breaches, violations, outages or
unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or as would not, individually or in the aggregate, have a Material Adverse Effect, nor any
incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority having jurisdiction over the Company and its subsidiaries or any of their properties or assets, internal policies and contractual obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification,
except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> or failure to protect would not, individually or in the aggregate, result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I></I><U>Further Agreements of the Company</U>. The Company covenants and agrees with each Placement Agent that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; the Company will file promptly all reports and any definitive proxy or
information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is
required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Placement Agents in New York City prior
to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Placement Agents may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> Upon request, the Company will deliver, without charge, (i)&nbsp;to the Placement Agents, two
signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each Placement Agent
(A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all
amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Placement Agents may reasonably request. As used herein, the term &#147;<B>Prospectus Delivery Period</B>&#148; means
such period of time after the first date of the offering of the Securities as in the opinion of counsel for the Placement Agents a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172
under the Securities Act) in connection with sales of the Securities by any Placement Agent or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments
or Supplements, Issuer Free Writing Prospectuses.</I> Before preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the
Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish to the Placement Agents and counsel for the Placement Agents a copy of the proposed Issuer Free Writing Prospectus, amendment or
supplement for review and will not prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Placement Agents reasonably object. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Renewal of Registration</I>. If by the third anniversary (the &#147;<B>Renewal Deadline</B>&#148;) of the initial
effective date of the Registration Statement, any of the Securities remain unsold, the Company will file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Securities, in a form
satisfactory to you. If at the Renewal Deadline the Company is no longer eligible to file an automatic shelf registration statement, the Company will, if it has not already done so, file a new shelf registration statement relating to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Securities, in a form satisfactory to you and will use its best efforts to cause such registration statement to be declared effective within 180&nbsp;days after the Renewal Deadline. The Company
will take all other action necessary or appropriate to permit the public offering and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to the Registration
Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Notice to the Placement Agents.</I> The Company will advise the Placement Agents promptly, and confirm such advice in
writing, (i)&nbsp;when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Prospectus or any Issuer Free Writing
Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments
from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by the Commission of any order suspending the effectiveness of the Registration Statement or
preventing or suspending the use of any of the Pricing Disclosure Package or the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any
event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a
purchaser, not misleading; (vii)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act;
and (viii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the
Company will use its best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any of the Pricing Disclosure Package or the Prospectus or suspending any
such qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur
or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of
the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will immediately notify the Placement Agents thereof and
forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Placement Agents and to such dealers as the Placement Agents may designate such amendments or supplements to the Prospectus (or any document to
be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein)
will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or
development shall occur or condition shall exist as a result of which the Pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in
the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will
immediately notify the Placement Agents thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Placement Agents and to such dealers as the Placement Agents may
designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so
amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Blue Sky Compliance.</I> The Company will qualify, if required, the Securities for offer and sale under the securities
or Blue Sky laws of such jurisdictions as the Placement Agents shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Securities; <U>provided</U> that the Company shall not be required to
(i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction
or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Earning
Statement. </I>The Company will make generally available to its security holders and the Placement Agents as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the
Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>[Reserved].</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities (including any cash
exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or the Warrants) as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>No Stabilization.</I> The Company will not take, directly or indirectly, any action designed to or that could reasonably
be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange
Listing.</I> The Company will use its best efforts to list the Shares, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and the Warrant Shares on the Nasdaq Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Reports.</I> So long as the Securities are outstanding, the Company will furnish to the Placement Agents, as soon as
they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities
exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Placement Agents to the extent they are filed on the Commission&#146;s Electronic Data Gathering,
Analysis, and Retrieval system (&#147;<B>EDGAR</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Record Retention</I>. The Company will, pursuant to reasonable
procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>FinCEN</I>. The Company has provided to the Placement Agents a properly completed and executed Certificate Regarding
Beneficial Owners of Legal Entity Customers, together with any required identifying documentation, and the Company hereby undertakes to provide such additional supporting documentation as the Placement Agents may reasonably request in connection
with verification of the forgoing certification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Reservation of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares and Warrant Shares. </I>The Company will reserve and keep available for the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants such number of authorized but unissued shares of Common Stock as are sufficient to
permit the exercise in full of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares. The Company will reserve and keep available for the exercise of the Warrants
such number of authorized but unissued shares of Common Stock as are sufficient to permit the exercise in full of the Warrants for the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Securities Purchase Agreement</I>. The Company shall deliver copies of all closing documents to the Investors pursuant
to the Securities Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Placement Agents</U>. Each Placement Agent hereby represents and
agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not and will not use, authorize use of, refer to or participate in the planning for use of, any
&#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and
any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by
reference) in a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or
(iii)&nbsp;any free writing prospectus prepared by such Placement Agent and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), a &#147;<B>Placement Agent Free Writing
Prospectus</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not and will not, without the prior written consent of the Company, use any free writing
prospectus that contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U> that Placement Agents may use a term sheet substantially in the form
of Annex B hereto without the consent of the Company; <U>provided</U> <U>further</U> that any Placement Agent using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially
concurrently with, the first use of such term sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the
Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of the Obligations of the Placement Agents and the Investors and the Sale of the Securities.</U> The respective obligations
of the Placement Agents hereunder and the Investors under the Securities Purchase Agreement, and the Closing of the sale of the Securities, are subject to the accuracy, when made and as of the Applicable Time and on the Closing Date, of the
representations and warranties of the Company contained herein, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to each
of the following additional terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending
the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the
Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in
accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Placement Agents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Representations and Warranties.</I> The representations and warranties of the Company contained herein and in the
Securities Purchase Agreement shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement and the Securities
Purchase Agreement shall be true and correct on and as of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I>
(i)&nbsp;Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, including a health epidemic or pandemic outbreak of infectious disease (including without limitation, a further outbreak or escalation of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or any related/mutated form of <FONT STYLE="white-space:nowrap">COVID-19),</FONT> whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise
than as set forth or contemplated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package and the Prospectus there shall not have been any change in the capital stock or long term debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting
(x)&nbsp;the business, properties, general affairs, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, or (y)&nbsp;the ability of the Company to perform its obligations under this Agreement, the Securities Purchase Agreement, the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants, including the issuance and sale of the Securities, or to consummate the transactions contemplated in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Securities on
the terms and in the manner contemplated in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officer&#146;s Certificate.</I> The Placement Agents shall have
received on and as of the Closing Date a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Placement Agents (i)&nbsp;confirming
that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representation set forth in Section&nbsp;3(b) hereof is true and correct,
(ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement and the Securities Purchase Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its
part to be performed or satisfied hereunder and thereunder at or prior to the Closing Date and (iii)&nbsp;to the effect set forth in paragraphs (a)&nbsp;and (c) above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date, Ernst&nbsp;&amp; Young LLP shall have
furnished to the Placement Agents, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Placement Agents, in form and substance reasonably satisfactory to the Placement Agents, containing
statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letters delivered on the Closing Date, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than three business days prior
to such Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the
Company.</I> Cooley LLP, counsel for the Company, shall have furnished to the Placement Agents, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date, and addressed
to the Placement Agents, in form and substance reasonably satisfactory to the Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT
STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Placement Agents.</I> The Placement Agents shall have received on and as of the Closing Date an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement of
White&nbsp;&amp; Case LLP, counsel for the Placement Agents, with respect to such matters as the Placement Agents may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable
them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Legal Impediment to Issuance.</I> No action shall have been taken and no
statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities; and no injunction
or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Good Standing</I>. The Placement Agents shall have received on the date hereof and as of the Closing Date, satisfactory
evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Placement Agents may reasonably request, in each case
in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Suspension of Trading</I>. On or after the Applicable Time there
shall not have occurred any of the following: (i)&nbsp;a suspension or material limitation in trading in securities generally on the New York Stock Exchange or on the Nasdaq Market; (ii)&nbsp;a suspension or material limitation in trading in the
Company&#146;s securities on the Nasdaq Market; (iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or
clearance services in the United States; (iv)&nbsp;the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or
crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the
public offering or the delivery of the Securities being delivered at such time of delivery on the terms and in the manner contemplated in the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Prospectus Delivery Requirement</I>. The Company shall have complied with the provisions of Section&nbsp;4(b) hereof
with respect to furnishing prospectuses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange Listing.</I> The Company shall have filed a notification for the
listing of the Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and Warrant Shares with the Nasdaq Market and shall have received no objection thereto from the Nasdaq Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Warrants</I>. The Placement Agents shall have received electronic copies of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, substantially in the form of <U>Exhibit B</U>, and the Warrants, substantially in the form of <U>Exhibit C</U>, executed by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of <U>Exhibit A</U> hereto, between you and certain officers and directors of the Company relating to sales and certain other dispositions of
shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Securities Purchase Agreement</I>. The Company shall have entered into the Securities Purchase Agreement, substantially
in the form of <U>Exhibit D</U> hereto, with each of the Investors, the Securities Purchase Agreement shall be in full force and effect, and the Company shall have satisfied all of the conditions to closing in such Securities Purchase Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Additional Documents.</I> On or prior to the Closing Date, the Company shall have furnished to the Placement Agents
such further certificates and documents as the Placement Agents may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Placement Agents.</I> The Company will indemnify and hold harmless each Placement Agent against any losses,
claims, damages or liabilities, joint or several, to which such Placement Agent may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the base prospectus included in the Registration Statement, the Pricing Disclosure Package
or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#147;roadshow&#148; as defined in Rule 433(h) under the Securities Act (a &#147;<B>roadshow</B>&#148;), any &#147;issuer information&#148; filed or
required to be filed pursuant to Rule 433(d) under the Securities Act, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, and will reimburse each Placement Agent for any legal or other expenses reasonably incurred by such Placement Agent in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however,
that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the
Registration Statement, the base prospectus included in the Registration Statement, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in conformity
with the Placement Agent Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Placement Agent, severally and not jointly, will
indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof), joint or several, arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the base prospectus included in the Registration Statement, the Pricing Disclosure
Package or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement,
the base prospectus included in the Registration Statement, the Pricing Disclosure Package or the Prospectus or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow, in reliance upon and in conformity with
the Placement Agent Information; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this
Agreement with respect to an Placement Agent and an applicable document, &#147;<B>Placement Agent Information</B>&#148; shall mean the written information furnished to the Company by such Placement Agents expressly for use therein; it being
understood and agreed upon that the only such information furnished by any Placement Agent consists of the names of the Placement Agents in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b) above of notice of the
commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; provided that the
failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of
substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of
this Section&nbsp;7. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent
that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect
of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release
of the indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in this Section&nbsp;7 is unavailable to or insufficient to hold harmless an
indemnified party under subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Placement Agents
on the other from the offering of the Securities. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such
indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Placement Agents on the other in connection with the statements or omissions which
resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Placement Agents on the other
shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total placement agent discounts and commissions received by the Placement Agents, in each case
as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company on the one hand or the Placement Agents on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Placement Agents agree that it would not be just and equitable if
contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Placement Agents were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to in paragraph (d)&nbsp;above
shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions
of paragraphs (d)&nbsp;and (e), in no event shall a Placement Agent be required to contribute any amount in excess of the amount by which the total price at which the Securities placed by them were offered to the Investors exceeds the amount of any
damages that such Placement Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The obligations
of the Company under this Section&nbsp;7 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Placement Agent, each person, if
any, who controls any Placement Agent within the meaning of the Securities Act and each broker-dealer or other affiliate of any Placement Agent; and the obligations of the Placement Agents under this Section&nbsp;7 shall be in addition to any
liability which the respective Placement Agents may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company and to each person, if any, who controls the Company within the meaning of the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Placement Agents, by notice to the Company, if after
the execution and delivery of this Agreement and prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or the Nasdaq Market; (ii)&nbsp;trading of any
securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial
banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or
outside the United States, that, in the judgment of the Placement Agents, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date, on the terms and in the
manner contemplated by this Agreement, the Securities Purchase Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>[Reserved]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Payment of Expenses</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company covenants and agrees with the Placement Agents that the Company will pay or cause to
be paid the following: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and accountants in connection with the registration of the Securities under the Act and all other expenses in connection with the preparation,
printing, reproduction and filing of the Registration Statement, the base prospectus included in the Registration Statement, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering
of copies thereof to the Placement Agents and dealers; (ii)&nbsp;the cost of printing or producing this Agreement, the Blue Sky Memorandum, closing documents (including any compilations thereof) and any other documents in connection with the
offering, purchase, sale and delivery of the Securities; (iii)&nbsp;all expenses in connection with the qualification of the Securities for offering and sale under state securities laws as provided in Section&nbsp;4(d) hereof, including the fees and
disbursements of counsel for the Placement Agents, not to exceed $10,000, in connection with such qualification and in connection with the Blue Sky survey; (iv)&nbsp;all fees and expenses in connection with listing the Securities on the Nasdaq
Market; (v)&nbsp;the filing fees incident to, and the fees and disbursements of counsel for the Placement Agents, not to exceed $10,000, in connection with, any required review by FINRA of the terms of the sale of the Securities; (vi)&nbsp;the cost
of preparing the Securities; (vii)&nbsp;the cost and charges of any transfer agent, registrar and warrant agent; and (viii)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not otherwise specifically provided for in this Section. It is understood, however, that, except as provided in this Section and Section&nbsp;7 hereof, the Placement Agents will pay all of their
own costs and expenses, including the fees of their counsel, transfer taxes on resale of any of the Securities by them, and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Securities for
delivery to the Placement Agents, (iii)&nbsp;the Securities Purchase Agreement is terminated pursuant to its terms or (iv)&nbsp;the Placement Agents decline to place the Securities for any reason permitted under this Agreement, the Company agrees to
reimburse the Placement Agents for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including fees and expenses of their counsel) reasonably incurred by the Placement Agents in
connection with this Agreement and the offering contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement
shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Placement Agent referred to in
Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the
Placement Agents contained in this Agreement or made by or on behalf of the Company or the Placement Agents pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and
shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term
&#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be closed in New York City; and (c)&nbsp;the
term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>.
In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Placement Agents are required to obtain, verify and record information that
identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Placement Agents to properly identify their respective
clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Recognition of the U.S. Special Resolution Regimes.</U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that any of the Placement Agents is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Placement Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any of the Placement Agents is a Covered Entity or a BHC Act Affiliate
of such Placement Agent and becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Placement Agent are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;16 a &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);
(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;7.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;382.2(b).
&#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;<B>U.S. Special Resolution Regime</B>&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Research Analysts</U>. The Company acknowledges that the Placement Agents&#146; research analysts and research departments are required
to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Placement Agents&#146; research analysts may hold views and make statements or investment
recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by
law, any claims that the Company may have against the Placement Agents with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different
from or inconsistent with the views or advice communicated to the Company by such Placement Agents&#146; investment banking divisions. The Company acknowledges that each of the Placement Agents is a full service securities firm and as such from time
to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions
contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Placement Agents shall be given to c/o Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019, Attention: Syndicate Registration (Fax: (646) <FONT
STYLE="white-space:nowrap">834-8133),</FONT> with a copy, in the case of any notice pursuant to Section&nbsp;7(c), to the Director of Litigation, Office of the General Counsel, Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019;
Cantor Fitzgerald&nbsp;&amp; Co., 110 East 59th Street, 6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York 10022, Attention: Capital Markets (Fax: (212) <FONT STYLE="white-space:nowrap">307-3730);</FONT> with copies
to White&nbsp;&amp; Case LLP, 1221 Avenue of the Americas, New York, New York, 10020, Attention: Jessica Y. Chen. Notices to the Company shall be given to it at Sangamo Therapeutics, Inc., Attention: Prathyusha Duraibabu, Chief Financial Officer,
501 Canal Boulevard, Richmond, California 94804, facsimile: (510) <FONT STYLE="white-space:nowrap">236-8951;</FONT> with copies to Cooley LLP, 3 Embarcadero Center, 20<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, San Francisco, CA
94111, Attention: Chadwick Mills, facsimile: (415) <FONT STYLE="white-space:nowrap">693-2222.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under
or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of
venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the
jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Counterparts.</I> This Agreement may be signed in
counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Waiver of Jury
Trial.</I> Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">SANGAMO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Scott Willoughby</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Scott Willoughby</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">BARCLAYS CAPITAL INC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">CANTOR FITZGERALD&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BARCLAYS CAPITAL INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Dan Cocks</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Dan Cocks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">By: CANTOR FITZGERALD&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jason Fenton</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jason Fenton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Placement Agent Agreement</I>.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Free Writing Prospectuses: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined offering price per Share and accompanying Warrant is $0.84. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined offering price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Warrant is $0.83. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is selling 24,761,905 Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is selling <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase up to an aggregate of 3,809,523 shares of
Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is selling Warrants to purchase up to an aggregate of 28,571,428 shares of Common Stock. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sangamo Therapeutics, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">_____________, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>ARCLAYS</SMALL>
C<SMALL>APITAL</SMALL> I<SMALL>NC</SMALL>. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ANTOR</SMALL> F<SMALL>ITZGERALD</SMALL>&nbsp;&amp; C<SMALL>O</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Placement Agents </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as Placement Agents, propose to enter into an placement agent agreement (the &#147;<B>Placement Agent
Agreement</B>&#148;) with Sangamo Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the offering (the &#147;<B>Offering</B>&#148;) by the Company, of common stock, par value $0.01 per share, of the Company
(the &#147;<B>Common Stock</B>&#148;) and warrants to purchase Common Stock (the &#147;<B>Warrants</B>&#148; and, together with the Common Stock, the &#147;<B>Securities</B>&#148;). Capitalized terms used herein and not otherwise defined shall have
the meanings set forth in the Placement Agent Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce Barclays Capital Inc. and Cantor Fitzgerald&nbsp;&amp; Co.
(each, a &#147;<B>Placement Agent</B>&#148; and together, the &#147;<B>Placement Agents</B>&#148;) to act as Placement Agents for the Offering, the undersigned hereby agrees that, without the prior written consent of the Placement Agents, the
undersigned will not, during the period ending 90 days after the date hereof (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned now or hereafter by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission
(such shares or securities, the &#147;<B>Beneficially Owned Shares</B>&#148;) and securities which may be issued upon exercise of a stock option or warrant), (2) engage in any hedging or other transaction or arrangement (including, without
limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which
reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part,
directly or indirectly, of any Beneficially Owned Shares, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise (any such sale, loan, pledge
or other disposition, or transfer of economic consequences, a &#147;<B>Transfer</B>&#148;), (3) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock, or (4)&nbsp;otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (1), (2) or (3)&nbsp;above, in each case other than: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers of Beneficially Owned Shares, Common Stock or securities convertible into or
exercisable or exchangeable for Common Stock (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (iii)&nbsp;to any &#147;affiliate&#148; (as
that term is defined in Rule 405 under the Securities Act of 1933, as amended) of the undersigned or (iv)&nbsp;by will or intestacy to the undersigned&#146;s legal representative, heir or legatee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) pursuant to any contract, instruction or plan complying with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Securities
Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that has been entered into by the undersigned prior to the date of this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the acquisition or exercise of any stock option issued pursuant to the Company&#146;s existing stock option plan, including any exercise
effected by the delivery of shares of Common Stock held by the undersigned; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any conversion of restricted stock units into shares of
Common Stock as provided in the applicable restricted stock unit issuance agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any transfer of shares of Common Stock to the
Company in connection with the undersigned&#146;s tax withholding obligation upon issuance of such shares pursuant to the applicable restricted stock unit issuance agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any sale or transfer of shares of Common Stock (including in open market transactions through a broker) to satisfy the undersigned&#146;s
tax withholding obligations in connection with the vesting of equity awards pursuant to the Company&#146;s equity compensation plans or arrangements, which are described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, and which equity awards vest during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) pursuant to a sale or an
offer to purchase 100% of the outstanding Common Stock, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties resulting in a Change of Control (as defined below) and approved by the Company&#146;s board
of directors, provided that, in the event that such a Change of Control is not completed, the undersigned&#146;s shares shall remain subject to the restrictions contained in this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement and title to
the undersigned&#146;s shares shall remain with the undersigned; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) the establishment of a trading plan pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Common Stock, provided that such plan does not provide for the transfer and sale of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period,
and provided further that, except as required by applicable securities laws, no public announcement of the establishment or existence of such plan, and no filing with the Securities and Exchange Commission or any other regulatory authority in
respect thereof or for transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall be required, and no announcement or filing shall be made voluntarily by the undersigned, the Company or any other
person prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any transfer or distribution pursuant to clause (a)&nbsp;above, each donee or
distributee or transferee shall execute and deliver to the Placement Agents a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in the form of this paragraph and,
pursuant to clauses (a)(ii) through (iv)&nbsp;above, no filing by any party (donor, donee, distributor, distributee, transferor or transferee) under the Exchange Act, or other public announcement reporting a reduction in the beneficial ownership
shall be required or shall be made voluntarily in connection with such transfer or distribution. In the case of any transfer or distribution pursuant to clause (a)(i) above, it shall be a condition to such transfer that no public filing, report or
announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such
transfer or distribution shall be legally required during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. For
the avoidance of doubt, any shares of Common Stock received by the undersigned upon the exercise of a stock option or conversion of restricted stock units as described in foregoing clauses (c)&nbsp;and (d) shall be subject to the restrictions under
this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In the case of any sale or transfer pursuant to clause (f)&nbsp;above, any public filing, report or announcement of any such sale or transfer shall disclose that the sale or transfer
was for the purpose of covering the withholding taxes payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreement, (1) &#147;<B>immediate family</B>&#148; shall mean any spouse, domestic partner, lineal descendant (including adopted children), father, mother, brother or sister of the transferor and (2) &#147;<B>Change of Control</B>&#148; shall mean
the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an Investor pursuant to the Offering), of the
Company&#146;s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become,
currently a party to any agreement or arrangement that provides for, is designed to or reasonably could be expected to lead to or result in any Transfer prohibited by this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for
the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;the Placement Agent Agreement does not become effective by March&nbsp;22, 2024, (ii) the
Placement Agent Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, or (iii)&nbsp;the Company notifies the Placement
Agents in writing that it will not be proceeding with the Offering prior to the execution of the Placement Agent Agreement, the undersigned shall be released from, all obligations under this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.
The undersigned understands that the Placement Agents are entering into the Placement Agent Agreement and proceeding with the Offering in reliance upon this <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement and any claim, controversy or dispute arising under or related to this <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Lock-Up Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WARRANT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SECURITIES PURCHASE AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sgmo-20240321.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 1:00:31 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:sgmo="http://www.sangamo.com/20240321"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.sangamo.com/20240321"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240321_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240321_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sgmo-20240321_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 1:00:31 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sgmo-20240321_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 1:00:31 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sgmo-20240321.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g816036g77j47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g816036g77j47.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1+J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $LZ^2!0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     !  E,S,  $  @"4S,P  0 ".$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!$0      !     "   "0    D      .$))300>       $     #A"
M24T$&@     #00    8              "P   "(    !@!C &\ ;P!L &4
M>0    $                          0              B    "P
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   "P
M4F=H=&QO;F<   "(    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<    L     %)G:'1L;VYG    B
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M  0 !__$ 3\   $% 0$! 0$!          ,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!08!!P@ "1$2$Q05%CEWM@HA(B,D)C'_Q  > 0 !! ,! 0$
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M88;?=:"2PPV6XU\*Y,)&5OMML.XF6KFLLCAEBAG'$A%FL9#S\DLG^Z!\1$S
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MMB?-@PIS.)I;%9(+E$OEE*A24.:I[BRKL7Y'D* 5EE8A*[D6"*"!T<U'2!)
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M)S7G"OC,CI%@D,EOSC&?1YE:?.,9\><=>&+6X)6U8-67P0, 3 H_I(E$C/\
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0&FHA*B:R0\Y<GK:Z:W7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140387342297904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 21,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\VMQ&7,&56 ;P/=KI<S[C3W$5K]!C/\%4$L#!!0    ( ("(>5B?H!OPL0(
M .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-
M0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DC
MO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-B
MK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@
MI+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTP
MY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RH
MC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#52?2$
M1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36
M-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO
M<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#V
MG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ
M+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,
M)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AME
ML,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>
MQ[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D
M3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    (
M ("(>5B7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP
M!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T0
M4FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7
MG:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B
M6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!0
M2P,$%     @ @(AY6!PX9>H_ 0  / (   \   !X;"]W;W)K8F]O:RYX;6R-
M4<MNPD ,_)75?D 34(M41+B4/I"J%I6*^Y)UB,4^(J\#+5]?)U%4I%YZ\GIL
MC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+
MIGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X
M 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MA
MA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6VP7#H:,1%=F6CSV&L0XAS^D^,L:JP
MA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3K'H,+"&I=1BH9+=S*J?7=G#-(O<J
M0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?
MM_P!4$L#!!0    ( ("(>5@D'INBK0   /@!   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*
MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L
MXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5
M&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFN
MWPQP>'3^ 5!+ P04    " " B'E899!YDAD!  #/ P  $P   %M#;VYT96YT
M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;
M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:
MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC
M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ("(>5@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ @(AY6#6G);;N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ @(AY6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "
MB'E8VDUS?U $  "/$   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ @(AY6)^@&_"Q @  X@P   T
M         ( !DPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " " B'E8EXJ[
M',     3 @  "P              @ %O#P  7W)E;',O+G)E;'-02P$"% ,4
M    " " B'E8'#AEZC\!   \ @  #P              @ %8$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ @(AY6"0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ @(AY6&60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d816036d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d816036d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d816036d8k.htm">d816036d8k.htm</File>
    <File>sgmo-20240321.xsd</File>
    <File>sgmo-20240321_lab.xml</File>
    <File>sgmo-20240321_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d816036d8k.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20240321",
   "dts": {
    "inline": {
     "local": [
      "d816036d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20240321.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20240321_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20240321_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-03-21_to_2024-03-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d816036d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-03-21_to_2024-03-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d816036d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sangamo.com//20240321/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001193125-24-076613-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-076613-xbrl.zip
M4$L#!!0    ( ("(>5B 3T0HX!8  #*!   .    9#@Q-C S-F0X:RYH=&WM
M76ESXS;2_NY?@5)V$KM*%W78DNS1ED>CF5'%8[LLYTWV_9*"2$A"AB(9@K2E
M_?7;#8"7;EN6/$F<VAU+) @T^GCZ $!=_'LZL<D#\P5WG?<_&<7R3X0YIFMQ
M9_3^I\M^I]?[Z=_MHXMQ ,V@J2-:%N/O<^,@\%JETG3@VT7!S.+(?2C!C5*E
M7*GF=,-0%(*9QT3<>DC%H.CZHU)T)]/<<1TGG,2-'Q\?B[)[?, *_!(^48)&
M!6C%?&Y&STUM[GS+//98E0\9S6:S).]&31=:Q@-4RN5J"6\/J&!1<S&:N)GF
M@CHC.G&+ICM!TFOE:L6(R1!\&1'0L5'Z[>M5WQRS"2UP1P34,>,APL!?25"S
M!'>CAERXM8IQMH9ZW2)^8+JJK0%M'9@K^^W#W572/%C>/FE:"GSJB*'K3V@
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M,]14V9JJ& Y$*LG(2X^$A?8D",ZGFF9$NN"'9>5>HPBND?E6M&J@02B%?9%
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MMM!KAAB/0L(NZT_.1B6+ZD= ,/VF0X?8&4?EOR"Q[&*\ "@]=$"_R0" 6"$
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M7O_>IHR%>/K:0Q@,.* %.@IS06YH%E#P5YL+^F=4"X+Y&9S>D%.7O<IICIL
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MLQ=UL"(H]%]24^7*YQTGRGAS^L0AY$;E,-&[0:5$+PEF(T]'+PO*>W@Q89H
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M"<J]1(*>>:F\(Y1,G6ZE$RTSK"##)$,HZ=>T!*S40X@$8>DW!4A!!X4/K(1
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M<.1(=W<DP&T-4-P.]]]J>%[KC"[?PE;FCMZ\P4 !HJ?!/I#=])WN/3>HR?#
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M<4>7CE6V/M-=EHWX.C1RC@GP;Y(%7@ZU1CLZRA\]M"B9P5SP4MYX0R"Z8%6
M[=JDN@KR?KQ+X1-KT;)BT<=LZILK7V\'TA,=55ZETQ24*"T '&H_VS#9R&.<
MWND-LNT>)6<;1Q&+XYE5X]$,_"+P/C**R<J:K%U2?.8U(:C%;-I=8PK[N#%V
M;MKAI>R=A ]VU9P!^DNL6J>:3<0IB?#TTZ*T5/Y=6/$SMN+[#Y0>'V>8^NLW
M19,(3#9WQ&#MIRN]RI+M6" *N9.-OYJP]3<>X26%WJ:F>SU&*'IA7$Y\I5]!
M.[R6370'MW^Z'QW7=*+2HN:K'15,G587V92D"6U3E% VE,<C:R+T7>Q@-:GX
M=H[)!*U(L-[!LREJE&',T"U RM NA@/ATQ>(%*H5">2M7/DGZJX:;H1DL\ZT
MV!M6AE'ZKU62XW-_^0_=CC.P83%%74[3=!:>'S.[\2A,+?C7O4IMD"-BYVX8
MZR" F,#2(L?F$OV:K5?!@ )B+=8D(*EDY<"A+3^AYH-%FZ4P$E:"Z(TA=&!K
M<!ZD_!ZK8(W1DU1@Y"B=W=,GEJ+@X(3!WL^'?.0W@<,Z3SE7!*^%,^%.Z#+)
M9@@CZ9I\L,#\UP&QN@L]--^/_BSMMO)LVLDN\F1IX(2G#-W\(*>S&RBQFPX8
MC^C6H?BV:D7&6="2D9>"6U?F;8F.P>]$NY_N@([+XI\J_DWJUE_UESK.,$N0
MN[IQ#M-D'6(8.WE ?@6X/LDJ)^U*#BV[Q&17P9ODM9WAD4X8C]P@X'*KU;S(
M..S/=S\JK>Y+<<<713;GD,8Y+DNOJCI/JD6.:6.='#X"SBSHE6F>9(LXFB4+
M."'D)7U&[0DZILKH3),*0&U5$^JCQDEBEI1B^3+I5I0H8S57S?!FL6%9T$JS
M%<*PZK1!R ]&8^'#@<'Y.-(@^E>_/\[X/J8@%CG#DG&;JHL;*$U1>FWDI/&@
M6SE(3&##A3$;CSB0U9'%SKX->J&_B%_OSU""=6P8<3T.(ZZ]P=9?I$ZF=T*D
MQ8-9-1H<%!SJ/U#'!G4!>+!?OWX;1X='1X=:)R$+<+P ?3E-ZG@\&D"\W__Z
M>_U 8%]+D$9X0.*CAX(\S-*VO=Y%@U7Z];J#F243R>WG>,30;KP:KX-PDU^A
MQTA3_>+@\>^G&[,<IS+1X<^87'8[MS,#34T!$5B3\<A_+C 2:+TR#9W /4NW
M/2XJZ/$*A,?#)LBD7<!/50;6SIQBL&!L+3(Z%O2YS@?@U@9UEU2DBT 1L8>Q
M2#Z)=Z4/KS5EI_Y-E)//)4,.XZ.<IG%WXYJ-'(R%Q>1F++(Z3Q/,/3^%^_OC
M,XE=SLAZUG"O$QX<#,5]JT (K23UARG-X'D=:G;?*2A'^-@\(\5+<2[QH1'D
M D9_IL^TF3&;&\87M L2YJNJR.ISKZ>,GM>DE]R2XU'[RW"=P/AKL(?1%%_5
MJ?/HAX4K9F >_I'6'*[&DLT -4%T,<LBE^O93L@/>++NG9'X.DXT[9?!&)]6
MV20EL),\NG5#89B1]>\!&$X6X@//"P51( TS%2^#AN"</M@D*,IH)#MC>].Q
MP_Q&&5WIC8,/HV7,_,7D\]O;QCP>Z:#I_.#(O]\@XX,?0<9;O6\F=-^<8C56
M%;V" QS]0[1&"%,X??:&O#V)9Z=#F+(>E$-H'!L0$./8W15M=>T%Y<["-_8E
M2MDIG";@4J+Z%*VP3V<!U;[B%&+">,2:>/HW_7N)EP!F\*NP;L%<?_H ^K[Y
MNOLV'+;* J768K+Y](+&,U%%=3$',(<=H :D#% Q-EFS:BB>Z&-SY/"QYX4>
MO4N;V,],5NOV@ZFFCI5H,,A.6KEJ;10F6(.=BO;,3B6MI]F5Q;LN3_">V<OV
M69MP-BJL[-LHC-;X-:]U#[0()]I!MVQMR/JP!7\$9MC>X?U]M,;X%@I2;<=L
MY3"B]<'##04!%8Q+!Q;Z&QX\(L@1">%)/)OB'U4)JQA593(#5Z*\=+%4GG:O
MA-5>JHT!@-;;[(+LCL%@STLG#6;]QZ/N!E ,+\_X#>C@N"M.;*&ZM^2"0);^
M6JWXB,&-MH>?EMN,(0KP-# I\%G9/+-GY,&#?<&L#7BQ'8QN*2'8AG%V>I5R
M18WXA&5:JZ#,X00U!FIH;0^Q@_W5NPU:.6Q!T6N-)1X-&.)W8H3SS&_="H_N
MS@A/=Q;U.[;8.]\=-M@W*\U!HQU\P&_.:K]&K?O-VD13LHDVH#B-:826$;GC
M Q\G"6+I[$;HG3H<AC@_W:1J+LF0:$.-S04N#T%/2 YYO8+!%*Z"*BQ<V0QU
M=Z.EVOU9]S6Q>D"2XJ ():G#A HLEA0_K>R]2_>JEX,GQSVK1-AEB8VV#!,Z
M:_XD.8C<AJ7.BJSA4A :&;@"<#?TS>:IT<J)#Z-<J3I ;^P0, ^'SB/F]=K?
MX2ET= :Q]^Y:=O8K_69]C6O:W$^A-?REUQ#,O/6)EGM+GYKIE8/?OW*TJ'/1
MA!=L?Z6&6V._GFA1>XR^[-.&VSIN/S+< YCZ53;A9M?]#F-PB#WYMJ[_KW:C
M(\;]>E?Z%F5P/=G]FI&[KOE\#2/@+N/P,XZ+V&J2%^J\^4O?^7.XU4.%)QOW
MLZ,U_/X.^P^7YPR:%OMZN'9)I'J3KR8B*WIX8;%0MO)&[_8BU03C>.2]6>\;
M75%#R>6]34G=E&[Z7J.@#W]$0;><]BL6;._FHJIB!<U'(1<O\'7IRHMG&VK.
MKG;T=X@<T,EOG[YDDPZ(U0XA3?#%>N"KV27]1Y[NE9N/1MS]?9/2??.*JRA@
M-9R4\&TS'N%U,W=_-DIP+^3$4)<()IC6>O7O.X/55-EDK+@Q;#RCKR#@,)ME
M284VJ$LT$9KSBP1\8\*L=08"GP5MQT%[V?AD?4+;8T[WW&FU>0Q?<6)K@CAF
MU2;GJ0GV [RRS)<K7&6=0\^$#(D9P9]GOJ*6@#WZN0S.T#*M#"J"))]F%>1$
MZO-HCK0]'AQ.@=7:1U:?LB'6*U8&[*6UGCUF,MA]*:.R%0JER$FNM@3)R9:Y
M&U?TL2#((8F(K#U'P9, Y$KE6I&43;BZ#1G^M!1@#D=Q+<9X2956\.8:^?)6
M^<W(\95D(G0<-CBWCM%L/.* OM\&^XP[.H<N7@(JE$"J+@%N]K=*,03?QN+L
M(O08>73X'%G6]NIASJ/07>805FN=0D^O=_N9\&MC"OVF;N=O('(YIUL$5NKO
M*IO',S@LX%2>D'Y@S^5])O7P03!D4=8-89)1T'N7.-QE(YA?[/U<03)CG^HC
MT7"I7I)6')@H>'GQ5/B(B:\RR%22O"%_8,'(N0$6.HH26%9!?E*Y) 4\'@7H
MLL#+M51U6>$+$\^(/0^>),]@!0;/F*G-DGZ&Q2)2.Y#<AM8:5@OC?<L<Z[?]
M:Y3HY\;6=S_&@U<U]XB%9I9.R&K+R^+,_F;NXM0:BI4:4CSW]JC'^K=91H41
MI,=F.-1LXJLBX.^?,L)G<C [)D8 N 1F5/ZH>-]8L-O"0=1.5,OVYPF'LH.=
M=^-P6CN1D\'BXL>97J1YN93@_469$[E@@NK*5Z ./H1CE@F'9\4BFZSJ#,/K
M3("+U,:X+'!@80-X5ET[(N91(VH8GH_Y[E^>BC#$UAXPE@#1.I1R$PUHY$ )
M-V!>%PP=IKJ=IR997:29'!0LQ)"G%,/;3*<PM02SQ-B(U1<)8_3QNYX\%_P8
M>CX&>$M'@0N7":Q$A52'JXH/FRZ>8""RVJ]]*WVVTQSE%EU5E<0J\BR99#F>
M,?1-'# \QDJJ*F67!;T<V$PY3S<P"K[Z8;5[ECO:=;7K56UB+@@8Y\G!N%3W
M<B03RV%D%7<9/BCSK:O(:H,?)4,G^V">(50F_;S$N#A*,1B@Y<Q5C<.1S),%
MR;!E$3Q/DQP&FB[AN"^R*4ER4LB_5PT%*F@9"CI6R T-&B1-"$?BGJ.%;7FV
M$! ,4B&JZ^Z? ]JUQG&H\MF!#_'DS7^?OKAW^*NI4&&(,;E:/R]6;-@Y!N=M
M-2_Z/$^JV#H/:N)B95T!"ANO*-)0M,JTW\E$%.FJFO -1C\N5UQ/39LYY57@
M^#[5YTPKIC @10F'K*';.ZDF&=X=)7WJ#%]>X#E-<DZR$8U/B7P;6K>/FTQE
MCYI.)X:KQ%8^S_BVV=7.NL(5]?VB&1_]B./=JOU[1O;OF^HL*;)_^W31'ZB$
MWHLIYJ/W5F=KV62&,::6KG7U22NJ/J:'BWN.[L4%+,",BFS%:).4TAF^U1F
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M,I3<2=I<4N83/80R1"IOK&D6;8O)V'/20:HG;/K1Y21M/W.P*E?P\P)QA.I
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MC!K/D [4=+#@]P@B/\QQ,:'2(4RVH W8TSEG6-V;/S'6Q4"Z!+*DGZ(RW6]
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MKJ LP^='QW.,[6'0,%RU2!<-3G%YN6\@Z[I!SV7%L:59< -3D^5 5P\"8HP
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M?.7@23(]IX251F5F'0_6S> ;L,>+0NWQ=RE2FNC2%EAPZM;(<4Z;$N"6K8H
M9V>'PGJ<9Y.,5G,@BH,)",<!HNV+O5K$_:B(8=EWM>9^G(D/3&>UBDC,J;AE
MLE;Y).ET#96LM4Z?7'#?):\R+*,+3K]5\:QWM:9'B>O:.L">79*"]["8\B;$
M@JT]98X51O#ORX0%&?2$L%>4G6)K1Y=O_ +^'1X8[&;@IC(?&G<?A6I?X;M;
MC\&=_@:$MBQ5:)]7Y:>TTDF^2M-KI@N-7,D5KAQZ<2"=(K6NK7GKOHWV2GDM
MU2/#4X_UR_LV,7N&>KB2 &0B#?:(UN6:K+EOW;US3*E]JCR()K0ZF+N>.L!A
MC%"PF5^S.;.:(?3)13N[#969P'L'MN^[ARLMEUZC&5@?-UIF1;8!VK^Q]PE1
M -$^4Q,W#)D1S8QOVKCKM@64XV@P>KIT[5!K<D.&3!U#DA.'C] L7I8;PW8
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M#NY-7>:S/D'.,/J<8?;.M<M,<MB&&9B_99&BO2\,Z"ZG"ELX*^$/\,X(Z=!
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MIW!X8X]'1H,CX>+EM.$"%"E9Z[#YW!AXD T4'Y+T!\-8_C/25JQ I"V\N<]
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M=ZZ'ZBXP+RS%0?"Q!5/A@));89,J._B[%\]SS2UP^<OI8IG.,N6O.948BTL
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MHKA1.&E?)]!9'2<!< M=I&O+&(>+JV/>N,I*]M1_9[.).AXY&]42O\FQIM?
M:B$U@R* 9L&B1;>Y9GSX7422VWB@Q?#J],]WVG$Z[&@_1(:[=]$^D1P9)CW7
M723Z0N<,DV]\#K>6,.EA;RILUC1'OYB#%:J3V5&6EAO\1XX3X'/M,5'\6MV^
M(LRRLTHVG8#+#:U_)4! A?[?;2#R\8] Y)?A0PELX>(_PHTX%1#],!CJ0!K!
M^^J5 +J2-+97G%6V]B$DQZW@E@6)=C.!:FAYXJ ,/:7+HN=@]*IO_9)JG]@?
MS";YS$JO2E4Y&#_>LC-ROB5V-R;Y4PV#\MRQ%!6E'A,_:HXL7(TRKJ/O=1>@
MN,D^XM^,(1J$2[!"Q4=P!EM2_QJ3]1(8PHJ^E400 @4I 8]1Q&ZI[!R]7-^?
M9:A_@NVVL\WAVS!XU(-R [0\_ZZ<83@A*]CMQ;_UF1QFGAYE-=QFT!<DDW>!
M#D)8N]<9Q)P38C<1EJ%.)O>6Y10N\%9,IN=",=9BUWQH'Z#]3<6$/35FA"EH
M63&]':6<21=$ 5 ]3-9WX,H>D4?]EH+5=?32I :?,[)J:\!7<^M9(>!9<G;\
MEW'B6&*3<7K:Q=P%\1*%GDA(WPXV(R:4RZJVZ]='^J<Z2T+L9+TM9586)*!X
M4'V<2V[40PF8%L: HO)=S4YY^'/' -W6/(3CD0BKRW,@ @,3Q_3D,PJ2.S]%
M4K !W,!C-ZBH"XVM13I;>W0T'U.^U0RVMC4<.>0.(]#I37X7D9T')(?OP=C/
M+I)<Y2S(\0B$@IFIM*QM'J2PXW;CM]AV?7-1$&>K=Y(WU!ZT?;I;Y #MQ:2*
MQQZPN'WX$!9L0]=T#:J:?H4]W=;E]+!,U;1\6I[B/57*%$BP2MT2H_;)]^,G
M@$0AQ^4P_R'8]TDURR431!Z SYX,"UM0^_$E*W87LOF09/-$^#]?".D19HUJ
M%M17&-!@I%;=78/8 ^"UX(W"\MX\]075MA,8>W;C$9=\.T4EE=WG CK5G&$
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MZJ;7"F#[V-Z#1[*]YWL[GZ^_Z35BY/WC-H@_9<=T@L$Z!4'V8>G\=##N?_X
M=QQXQX,X3LJ:5*LYTZ=Z=B;U%#)OM6JM,C]R7]_\N%[_6-^L?')FC=-V21/_
M@G<Y_<4I/#V]1,.^5I7A4Q/0 "4*O4J+VNY3XS>=QO\,VR=<[_VZX37[87Y)
MN*4[]DH ZQU4ZW4P[ 5W,6Y3T)\07((.O)LGV7K-)<AT?SJ!IWA'8/!'[: ]
M\>&-47@+LZHJ4EB6D"EB>[,*_413[S">(*9,TO7!7>KT[V(L_6MB'FJ<#*/
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M&3<@ [8)4K+M]L-!MV!Z/BT%=4,6 >(]B,& F)U)1'WB<9@,(^)48UZCH@R
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MYM?&=:L81JA@UN';BZ-?X<.O-V>G!_\/4$L#!!0    ( ("(>5B?/^M#&T@
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M]X3%YW"%\N4EL)TR?"!C,^<3J"QPY,>-LBD= -5&8,M\VW#J_RBKSW)%[1W
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MP)9K6S=]WB1DFH0*)L(3'10Y=,HFB1=C"B\VC3Y!"(N;NA^^]Q ^_*@^)*:
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M<6;RKO=T5HQ>7M(7S?)Y?;WQ*82%6D$'XL</4O?8&R:L_.15M!)(H*VNPI<
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M?,-ILA#C^T6EXKQ:NE[S5.458>J5!UJ/YRH):!.$6H;Y9ZHTEA49@X(XM7>
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M@-YUG-5PVC2*<U78VK^]/HL5#?/BG*NQ$I_39>@&MG#HSCSLPH&UM3#^WFK
MMKQRQ]JFDW<H57I 6#LH;H7U99U*3-RZ;2HJ1DBE8KI/Q#5WI;]' P_ZW=MM
MDNP+6FNE'M^!VS%A.]ND9[+)RM5UA'J 2WTEY;1./E5_=C#C\,4M_]2-?"K7
M@@<$8P9>BJ#"6#C=KJG*S4. 'FT!=>+KLA+*L)]!!](@U15W'X>'^\4WK;KZ
M4@N?<V8\75O<]:&Y)&)5FM"0!KG.+*LF,L63'G"G1WN,4FJ)#HDJ,_Y9)_4
M\@BX3<]'D Y'(!V6E_8PU4764=^)%B[G ]I+3DV2*C8-J5&Y*-Y.>HV]UZMJ
MC7H>WM6R\H2BHFK< ^12(0?450R$ZVZGY(42?S^ZLT7U#W3.:P%PXTEC89J!
MP]K&$,.!E='TUQGS?#>EU&^>.\,RI9,)F28HG&T;E &ZB4 _Q*L+:B&>Q"F9
MUP,":7(VD_=QJ]$N\#%7#GXU+G#CTT%+J/L:?U\DQ@^#(C]R^H@6[PD!!/86
M7\6?_)DI>ZZQ()L/H/ U#BORO1Y$%A$&H]Y"_B</7?RC,W.!_)\LE/^M[;YW
MX>[.3^I3MJ:XO/1'9#K]_JVZ1?_^Z!:]6[?H#76[@"$]$,TN8'6]K-/7HE9*
MVSVM3[T387Y=[6[!VU;M9GC1C/:7KM;L>*JNI/0M-+WDSU?T'D!1QS?S8IQ.
MN5+GB9/_VM4JE.W OO.P#&%+U[.1[0# P&5;,? ):@:6&^=?20?PG7B4B8$$
MZV:BSJ1:>F)7IYQEA &L,L_&KC$S![9(?O+)?*1N;0,ONMTWJ<2?D_\^M!8'
M26Y(.\FS$=;!'4A75U:N%+<R8*38I5K%5G_5-&*NIDKM1BALV6#G&H;.<5E)
M3[=UVY*"HE@)Q*QS=U9(I@Y<$8".M'G'%30O,=7%N*E2%C1IAF0R<U,!5:\Q
M($09I0B\575UE;86>RNY[?0W<^ :*J/.2@!#[5PVX5,T7RP0@]JZ:\I.&_@<
M'NHJ$IXJ5^..>I&>8M%2)V:H1FCW3?2PN7EY,X*W9;:?YZ13;Z=:FJ7SL1%G
M.$,\"&&,N-^O"_1[<W(0MA<;%F'CNP5#^P1KG-^ @F]ZJ]JV!"B+U6E:>&&/
M=BC$6G4><KQ"##-W[YCG-;8@Y5+G=E>[*WO&4&WK/\YM.B-%\CAU6@<;7_-8
MN$O/G>\@<J#Y=,I)7\M+UK[C%5O*=_?*3M:ZUGW?^966970H[>C4X&KX!]J/
M:W#7O"2'3NMP55/;_$N'"/S*#$7-$5"G_$GL[_IJRNYS)9,M&!J=O<*IPZDL
MWN((%-)G=G68FNVB Y*IP+R5IF=;LC#*MK>OC3, HUJY73$CVJ"@A0=]J6?Q
M5QN,2+P=4?C%R49].-:6@UMQ>C8XCKR9#I]K/K,/0F.E,2X:I9S42L%ZZ.<,
M"?2^-;"@:(W&P/()K (G)1=%TR_;X/V='(P(#(_!*[VOM A&^ZWQ"3."M$-C
M]8Y@><D_ XP=!ZB :[@&7+.N1?F>_5'%KTP/A*DC 6YQ9ZTB&3UYMQUA4U?B
M?H9<N5)@*$78).JCR MZ1<]))D.*F2J&S/:%Z7O<7L:P%0+R]KJS1[N81LM+
M/=O=EV(+LQ?+I6/U,$\Q!7KG61#UV>Y&@C"37#S;1Y42E8'1G*?YW-97&6>H
M.U%+ Y@2+*UPO59[WD<Q^QX5"21X16VEC*19G)6T!IM_OU #8E>-;45-Z^K=
MRF[K=:AOMYZ\UA1ZM[%QZ656'/2ZWEQ5[X5'3N%UR2!RA<ZY)%/8F$BGA4<4
M3BQL]Y%Y:T.@H,"0?1ZGBO"BS5XEZ[76W7+UC[H47[7Y^WB:[30J#5QX9G5[
M:I8Z^/:/NM=)>/A6YRB[:H=EP#4(:B*\N,$0/:MB4*>%5MIB3E/3640^[3UC
MIW0:18+9$BXT.I<WD%))BK/Q1* 39N1U$=SF%%E:3Y?:+G3&>%7RJ.IY92'L
MH;O8@=#1W3K+4\X554*Y7+4A=?'KYQ8:HNW8(QVIE^Q/6ER.4PQ#$+RLMW73
MOU7WZ0^/[M.[=9\&UZP(K3Z_Q(G3"=%<BU6[8TMP^T1P<=H2:A @["D9QF8A
M>@T[_#Z1H5KJHZ4\L+\K/^ !8Z]UA0/&(YD]EBV1<X>8/H>SR1$T,GYBDVV/
M7&K-N; N%*I0YZW\ :L'S@M/D1B#R@ \X7JJI(/!2K;(\E*+A5M+GAU.?ATU
MRX-T@^,SLXW]QJQ!Z^9D!+=G-A9XQH2%]6R99ARX+DM(69%"36D5#*''\C5D
M@G;IZAKM%3,>._/A5K660'YQZHY(*A=SOU6_7:^J25=&"+D\A;5 %J<V72].
MN%"EOQX5#"@-7>W_.,]-!"G7W0E?QP_8LAH.C]JSQRM8**SASC3LMX4;-R^:
M'E5WP9ZVLL,7$3B.8P<-)^AB_@*M8R7/@P%JF[HK"<AB5:+MX7Q7&[^47!_X
M.MSIQE/U#:A#Y30;^>OW^5.?(\$ZI?P@2L]V2'=Y.E)L<M;+@Q9</Y>"]4G!
M>E$[4E56%ED![6O&;(BT##(/>:I#P^_/&FIWIMMHJZ/5):M,E"%)O-*B$33
M?842W,/D79XS5D[S:G"QB/(JH_SPH\T<G1#'!+TKM7ILO$XY LQ(L(1B*"^4
MO5#X1\Z6C626E[' 4N^FHLZ57+#"C5$3C&[FVI;=+! A$>3JPKYW8RURHJ]@
M%$6[Q"@^XW7[51YCW9R4O-Z#6VBEP%)A =OADHIB,7"&L#Q^<FTKM38LJ(<B
M&G- ^F0YQGDI7-!OQ]IED$L"3\-K '_-=)&O5226^[C9*G&"Z-HAU=Y]VH\?
MCPQ998?2M7,D7F[_,^I-1ITCI>L@<2E7$.<Z]?F>26%#K[S==;UN00YF3PHS
M8U-2L:.)4;0C9ECT%;13C7BK#_'*4KH@4[26;F>*U#/L51SU85WD0+-U]N8%
M%;2)1)0%'# <CM(2.Q)Y2^J\AW'-)MG\JW4.D(QJYRQW-M.,$?*L&0QM 1(M
M77E%/W%T)W"D/:@?2.3E%1H ILL,_P*5'Y+CA$L*%(>L9=NZ"09E0WP[I(_&
M=0MEL5<?D<QZ><G+J1#*$K03D18KI"YAG,IQ$#D)?U-!$*$JO:QN;[BP9H%E
MC;B+F/%9#;P$\8X@@[R\:<'U^O770FH.=6C,@5$7I4O??+Q6Z(#_71!>$05D
MF-:9?6UO_DZH#+O3O4$S68M<#)<>F%"Q 9>,09T;9GGN1=Z=3]PWA<184MG9
M@T+2/HBR"ALSD>V63N+1#KL\D7FWUD8J*-6)<8ZO:)\>@#R;,%@9#,1?4$N^
M86ES9<=^H3]@Q;QLJ7#?><LE=PZC_'EYP2HCS"&P5*):>:'3\EMUC;U\=(U]
MO6S>YS:;]T1+X[C<P >5S:OSDTH+/+=C5^DY+D),FH/+Y?*X49Y>U%&7#ZV$
M+E@DZU[@,%5C7XTXK<Y6N"(GI/=VRZ(3L"^PWP+1D6A$3;P&/-:T=) N@^ O
M+E]Z:CAR'M8#=DX_U[P[?FWHYQ*%8G*=#M]!Q15Q1M%$*!(/)UT5ANW#"6Q4
M';7NGJ6<]NQWZ\9B\NFE$ZHXOG0,5CU!'Q<S7^(?NJ=4MC";6!UN$$3+NLHJ
MR7IHFBHH4[ 9+NP&E:[LN&S/\I+?9YWWUC!(3GZNN:VY)2W;!YG#U.A0*2PV
MP?^]3MH%?#Q)C#J<!_ESMC=GE8E@X4?*>"&1&.\K3(\Z<%WJ4FQ;%-]0YW=B
M$=M9PVUO; $N#M8X239QE1-TQ*BDKM;B'FB!D*"%#B_A+*QCY8'YVCG*; *?
MI>?<Y-G? 3:['@"[XE3@0S<UV_P]:BN$V0:4<S-V&<Y&?*)A27R^,5*;G6E+
M6Y>+0P %6YUF8X3.W!EG$6\&4^VE+4N<3J7&4DC<UMKQ3J7V,BOX@.#6,J&T
M*OIWLIA%+'YY*3"IGH.@&'@UH2WS"2K49,5YF9][-[ GR_Q.^$D4QC"=STG>
M20<E=)2G9@P!'PR[5-S[V.^ K%567OLXQMH9NF/-1$H.B+50B83:-%*^5YCS
M)*O ;I_94H>1N'0UX_&> "O,U<?G/8C&V:SQ,!6]]0<ZZF2Q:'H -YK3%77"
M1]*$2F]U3"54HI #2Z9B\_Q"]^TTJIM@O7;M8;37%=QH/QTB-":(+["A7EN?
M1J9%:2)\,Q-AVMB 0"O\V5YB#&DK+ M0#B-N AL?Y$JXK?XTLBONOG?7K2:M
M300MQ06[P6Q6W%A-;;5=L%#4B&<;6*].BUR&Q0^[2M)2^?39K,PHVHBW.S@^
M!NKX$$3R#K4#SH*A: V@G(BR#,;ZF#?@\A(C!"F&PS&&RR@3X68O=+@XTE8O
M.]YYPQ$=A^E-,G")HJ#@U(W%+"O(!B\'G$1M<<KDOM5Y.N3'57?':@5$XO.*
MG1VCQ@-4]0T6J3J,.RELN7!R^O-7!4(4;8+>-\Q^PL(RS#&YG 5^/,#N;E2Q
M#T0W HU68S]-PRIGZ'7)T5^:CL<5^K40N'2&C;2$*\=7-&0=2%KHC$YL!S&Y
MH[9OWEL/3^IS=+Z+Z1"(#$4<\1Q5,CH"B0'D31X3:AEWI,KZG4/(-9GGVEA,
MG?(#?#EY4Z7P>G!1U9^R*'?]/JIAO;#V\_NL1BTY+4PY?UAUL Y+K3P!ITS.
M(5&Y/Y'35EU/'5KJN)2.A9+DY].N:%GGI9?$,[!)Y#5E:? )5_;E*;M=0TRS
MTFX088YI"Z^!55!:4./[KVC 2O^[LJX'RTMP(R<@G/<,VG8C-07?PXUP<:7
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M.4KYM$U>PS3R-&C\H-E6' WB%]E>O!B1U4(1_)*6<TF4I0)V4.$].'/_%0]
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M@-=X@9X\O>!,8NW(!@H9)PER$C*QHZF?OG12I<0=WJ?59],LU,92YW"S3NG
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M91_]K6$_0L?.$(N_2">+.,,H!@5O@$"R-!ZE&0J5,2LS0R3).9C"XGK A_\
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MCJ'P2H@5@D4[1K ,TD^3D<3CC\ OLF1RQ@8M6RR,41TA3".N[%GZ?)@& B4
M?A+/SX<NB-?5-=J((EBN.9CA\FVQQ#)UW?K.S61EY P(.^?4 13FR#Z(@U,T
ME4Z93[ZJV86MUMDXB:P'>N?5:S&"XHLBG>CV38K%J#:22?;=N(9,AH1W70S$
MA,C9JCCJ>FO Y^D9-"0=[:N=ONB6@#0H1J!;*X8$>'I2UUGB[37BX4&4#3NB
M()X>=?=QCY&O^8IK$Y7>TW.KE(JCQ:0Z]'LWR5#XZ^;ZQL;0S7EA\Y14'^#I
M1.X34:C2E@R0<'HMD.:[!@K")KY+T!N?CBM?\[L% ^?%;011*65 5/SFE?^
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M%;I\.R2=E$2P>89-W[?C%:&"@V331=S1V1!UEXE;%4Y\SDE1DWS+9L&5EI
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M]2&Z-O\6,2YSH"'>1W&!7*T9&A(LE>O2:O-&.YL-9.KX&+S2T;S=7*BGU3>
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M[YR.PW=&,=';RH;^EEXN!VKH<_IK4+I_?R[CBNLYE-3KRM1=-NU&;F-#7(?
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M5PYON]/)1-#68#12D?;'^$6LZ;?52GNKOKO3JN\UMT4\P6WQPRMN^'WI!CI
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M>A/4G@X2N,GO>:.,PRE^GSMO@*K9K!N(YIV)['8I>,.;AOMY'0%9:D#8K[N
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M=;T43USK(_-W)[)3-/WK"_K,?U!+ P04    " "!B'E8X28J3K8$  !Z*@
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M+FAT;5!+ 0(4 Q0    ( ("(>5@QW$ /;XX  )?1 @ 1              "
M 9^E  !D.#$V,#,V9&5X,3 R+FAT;5!+ 0(4 Q0    ( ("(>5B?/^M#&T@
M !MJ 0 0              "  3TT 0!D.#$V,#,V9&5X-#$N:'1M4$L! A0#
M%     @ @8AY6/HN'E<030  (GD! !               ( !AGP! &0X,38P
M,S9D97@T,BYH=&U02P$"% ,4    " "!B'E8S0BUOB\/  !4.   $
M        @ '$R0$ 9#@Q-C S-F1E>#4Q+FAT;5!+ 0(4 Q0    ( (&(>5BN
M!7^9/0,  $D+   1              "  2'9 0!S9VUO+3(P,C0P,S(Q+GAS
M9%!+ 0(4 Q0    ( (&(>5A9IC0?7P8  +Y#   5              "  8W<
M 0!S9VUO+3(P,C0P,S(Q7VQA8BYX;6Q02P$"% ,4    " "!B'E8X28J3K8$
M  !Z*@  %0              @ $?XP$ <V=M;RTR,#(T,#,R,5]P<F4N>&UL
64$L%!@     )  D .0(   CH 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>d816036d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20240321.xsd" xlink:type="simple"/>
    <context id="duration_2024-03-21_to_2024-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-03-21_to_2024-03-21"
      id="Hidden_dei_EntityRegistrantName">SANGAMO THERAPEUTICS, INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-276">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-03-21_to_2024-03-21"
      id="Hidden_dei_EntityCentralIndexKey">0001001233</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-287">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-288">2024-03-21</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-289">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-290">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-291">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-292">501 Canal Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-293">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-294">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-295">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-296">(510)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-297">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-298">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-299">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-300">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-301">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-302">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-303">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-304">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-03-21_to_2024-03-21" id="ixv-305">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
